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“In Praise of Learning” 
 
Study from bottom up, for it’s you who will take charge; 
it is not too late! 
Study the ABC; it is not enough. 
but study it! 
Do not become discouraged, begin! You have to know everything! 
You must prepare to take command, now! 
 
Study, man in exile! 
Study, man in prison! 
Study, wife in your kitchen! 
Study, old-age pensioner! 
 
You must prepare to take command now! 
Find yourself a school, homeless! 
Look for knowledge, you who freeze! 
You who starve, reach out for a book: it will be a weapon. 
You must prepare to take command now. 
Don’t be afraid to question, comrades! 
Never believe in good faith; see for yourself! 
What you yourself don’t learn, you don’t know. 
Question the reckoning, you yourself must pay it; 
Set down your finger on each small item, asking: 
where do you get this? 
You must prepare to take charge now! 
 
Bertolt Brecht, Germany, 1931 
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1. Introduction 
1.1. The adrenal gland 
The adrenal glands are located in the retroperitoneal space, above the kidneys or on the 
inner surface of their upper limbs (Whitehead S., 2013). They contain two main 
compartments, the outer part consisting of the adrenal cortex and the inner of the adrenal 
medulla (figure 1).  The medullary part constituting 10% of the adrenal gland has a unified 
form and is responsible for the secretion of catecholamines. The cortex is composed of 
three different zones, namely zona glomerulosa, zona fasciculata, and zona reticularis 
producing mineralocorticoids, glucocorticoids, and androgens, respectively (Xing, et al., 
2015). Perfusion of the adrenal glands is complex, but mainly facilitated by the aorta, the 
lower renal artery and the kidney arteries. These branches create a complex grid from 
the adrenal cortex to the medulla feeding into the left and right adrenal veins.  
1.1.1. Adrenal cortex steroids regulation  
Steroids of the adrenal cortex are produced via a network of enzymatic reactions, mainly 
involving enzymes of the cytochromes P450 (CYPs) family (figure 2). The presence and 
function of these particular enzymes in the different zonation of the cortex highly affects 
the identity of the hormones that will be produced in the region (Nishimoto, et al., 2010; 
Payne and Hales, 2004). Steroidogenic enzymes are located either in mitochondria, such 
as cholesterol side chain cleavage enzyme (CYP11A1) or 11β-hydrozylase (CYP11B1) 
and aldosterone synthase (CYP11B2), or in microsomes of the endoplasmic reticulum 
(ER), such as 17α-hydrozylase/17,20-lyase (CYP17) . The main molecule necessary for 
the initiation of adrenal steroidogenesis is cholesterol, which physiologically is abundant 
in the blood and is mainly absorbed from the cells in the form of low density lipoproteins 
(LDLs) (Miller, 1988). LDL enters the cortex cells by endocytosis and is consequently 
hydrolyzed to free cholesterol. The next, rate limiting, step of steroid production is the 
cholesterol transfer to mitochondria by steroidogenic acute regulatory protein (StAR) 
protein and its conversion to pregnenolone by CYP11A1. Further conversion of 
pregnenolone to product steroids depends on enzyme expression and therefore follows 
a different path depending on the cortex zonation. 
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Figure 1: Schematic view of the adrenal zonation. The adrenal is divided to two main 
compartments: the cortex and the medulla. The cortex is separated in three zones, zona 
glomerulosa, zona fasciculata and zona reticularis, responsible for production of 
mineralocorticoids (i.e. aldosterone), glucocorticoids (i.e. cortisol) and androgens (i.e. 
DHEA), respectively. Medullary cells are responsible for the production of 
catecholamines (i.e. epinephrine).  
Mineralocorticoid synthesis 
Following the conversion of cholesterol to pregnenolone, the latter is transferred to the 
ER, where 3β-hydroxysteroid dehydrogenase (3β-HSD) converts it to progesterone, 
which in turn is converted to 11-deoxycorticosterone by CYP21A2 starting 
mineralocorticoid production (Hu, et al., 2010; Miller, 1988). The main mineralocorticoid 
produced in the zona glomerulosa is aldosterone, but also its precursors, corticosterone 
and 11-deoxycorticosterone, have mineralocorticoid action.  CYP11B2, exclusively 
expressed in the zona glomerulosa, catalyzes three steps in the production of 
aldosterone: 1. the conversion of 11-deoxycorticosterone to corticosterone by the 11β-
hydroxylase catalytic subunit; 2. the conversion of corticosterone to 18-
hydroxycorticosterone by 18-hydroxylase activity; and 3. the final step of aldosterone 
synthesis through 18-methyloxidase activity.  CYP11B1, which is expressed in the zona 
fasciculata, catalyzes the production of glucocorticoid cortisol but is also capable of 
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converting 11-deoxycorticosterone to corticosterone (Bureik, et al., 2002; Miller and 
Auchus, 2011).  
 
Figure 2: Schematic representation of adrenal steroidogenesis. This figure features all 
three steroidogenic pathways from zona glomerulosa, zona fasciculata and zona 
reticularis as indicated in square brackets. Cholesterol is the primary substrate for steroid 
production initiated in the mitochondria, where it is cleaved to pregnenolone by 
CYP11A1. The next steps include subsequent conversions of precursor steroids to end 
products. Due to the different expression levels of certain steroidogenic enzymes within 
the three zones, end products and also some precursors are unique to these zones.   
Glucocorticoid synthesis 
In the zona fasciculata, pregnenolone is converted to progesterone via 3β-HSD and then 
both of these steroids are hydroxylized to 17OH-pregnenolone and 17OH-progesterone 
through CYP17, respectively. The next step for glucocorticoid production involves 21-
hydroxylase (CYP21A2) catalyzing the conversion of 17OH-progesterone to 11-
deoxycortisol. At this stage 11-deoxycortisol is transferred to mitochondria, where it is 
being converted to cortisol by CYP11B1.  
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Adrenal androgen synthesis 
Adrenal androgen synthesis takes place in the zona reticularis. CYP17, apart from its 
activity as 17α-hydroxylase, can act as a 17,20-lyase thus converting 17OH-
progesterone and 17OH-pregnenolone to dehydroepiandrosterone (DHEA) and 
androstenedione, respectively (Miller, 1988). Since 17OH-progesterone is not an optimal 
substrate for 17,20-lyase, most of the androstenedione is produced via DHEA through 
3β-HSD. DHEA is subsequently converted to DHEA-sulfate (DHEAs) by sulfotransferase 
2A1. In addition to the aforementioned androgens, low levels of testosterone can also be 
produced in the adrenal. Androstenedione and testosterone can also be converted to 
estrone and estradiol respectively by the enzymatic action of CYP19A1.  
1.1.2. Physiological metabolic processes of steroidogenesis 
Physiologically, the secretion of glucocorticoids and adrenal androgens is regulated by 
the hypothalamus-pituitary-adrenal axis (HPA), and more specifically by the circulation 
and secretion of the adrenocorticotropic hormone (ACTH) (Ruggiero and Lalli, 2016). 
ACTH has a direct as well as a chronic effect on the adrenal cortex, regulating immediate 
steroidogenic responses and adrenal development. Chronic ACTH stimulation can lead 
to adrenocortical hyperplasia and hypertrophy, while reduced ACTH leads to 
adrenocortical atrophy (Miller and Auchus, 2011).  
The main mineralocorticoid function, and especially the one of aldosterone, is the 
regulation of blood pressure and potassium homeostasis (Atlas, 2007). This is achieved 
by aldosterone binding to the mineralocorticoid receptor on the epithelial cell cytoplasm 
of various organs, mainly on kidneys, regulating H2O retention and blood pressure. 
Mineralocorticoid expression is regulated by 3 factors: angiotensin II (angII), potassium 
levels and to a lesser degree by ACTH. Potassium and angII stimulate aldosterone 
expression by regulating CYP11B2. AngII production and consequently aldosterone 
production, is defined through the Renin-Angiotensin-Aldosterone (RAA) system (Figure 
3) (Hall, 1991). The RAA system is responsible for the physiological response to low 
blood pressure or low serum sodium. The primary function of this system is maintaining 
normal sodium blood levels and subsequently regulating blood pressure. When blood 
pressure levels drop, renin is released from the kidneys, due to low sodium and low fluid 
volume moving through the nephrons. 
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Figure 3: The Renin-angiotensin-aldosterone system is a blood pressure regulator. 
Blood pressure decrease causes renin production from the kidneys, leading to angII and 
aldosterone production. Both of these molecules cause water retention, vasoconstriction 
and subsequent blood pressure increase. Higher levels of aldosterone detected by the 
kidneys reduce renin production thus acting as a negative feedback (Hall, et al., 1986).  
 
Angiotensinogen, the precursor of angII is produced in the liver and cleaved by renin 
leading to angiotensin I production, which through the Angiotensin Converting Enzyme 
(ACE) is converted to angII the only potent angiotensin molecule. AngII causes direct 
water retention and vasoconstriction leading to blood pressure increase (Hall, 2001). On 
a cellular level angII binds to Angiotensin Type 1 (AT1) receptor, inducing inhibition of 
potassium channels on the cell surface and therefore cell depolarization(Hughes, 1998). 
Voltage-gated calcium channels are activated by increased membrane potential leading 
to a calcium influx. This calcium increase triggers a cyclic adenosine monophosphate 
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(cAMP)/ protein kinase A (cAMP/PKA) cascade initiating transcription of CYP11B2 and 
aldosterone increase (Figure 4).  Sodium retention and vasoconstriction result then in 
blood pressure increase, followed by aldosterone causing reduced renin production as a 
negative feedback mechanism. 
 
Figure 4: Schematic representation of the molecular mechanism for triggering 
aldosterone production. AngII binds to its receptor on the cell membrane leading to 
blockage of Na+ and Na+/K+ channels and consequently to membrane depolarization. 
This results in increased intracellular Ca++ levels, which in turn activate the cAMP/PKA 
pathway, stimulating CYP11B2 transcription. The produced aldosterone diffuses through 
the cell membrane into the blood stream.  
1.2. Adrenal cortical dysfunction and therapeutic challenges 
Adrenal cortical dysfunction is associated with many pathological processes including 
disorders of blood pressure regulation, immune function and salt and energy metabolism 
(Gallo-Payet and Battista, 2014). Dysregulation of steroidogenesis is a central feature 
for these conditions as well as many specific genetic disorders directly affecting steroid 
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production and metabolism (Miller and Auchus, 2011). Many of these disorders are 
characterized by mineralocorticoid excess like primary aldosteronism (PA).  
PA is one disorder of steroidogenesis and the most common cause of secondary 
hypertension that results from autonomous aldosterone production from one or both 
adrenals (Vaidya and Dluhy, 2000). It is defined as the group of disorders demonstrating 
autonomous increased aldosterone production, which cannot be contained after sodium 
treatment. Aldosterone excess leads to suppression of renin production, increased 
sodium reabsorption from the kidneys, increased potassium secretion and finally 
secondary hypertension.  
When involving one adrenal, effective PA treatment can usually be achieved by 
adrenalectomy. When both adrenals are affected, in which is the case for at least half of 
all patients with primary aldosteronism, the first-line therapy is mineralocorticoid receptor 
(MR) antagonists, such as spironolactone and eplerenone (Deinum, et al., 2015; Sica, 
2015). The latter offers an effective regulation of arterial hypertension and protection of 
other organs from aldosterone excess. Eplerenone is a more frequent treatment in the 
last years, since it does not stimulate androgen production like spironolactone; however, 
it is less potent and less stable requiring more frequent (twice daily) administration. MR 
antagonists do not protect from pathological MR-independent effects of high circulating 
concentrations of aldosterone (Monticone, et al., 2018). This might be the cause of the 
higher risk of incidental cardiometabolic events and death in patients with primary 
aldosteronism treated with MR antagonists compared to other hypertensive patients 
(Hundemer, et al., 2018).  
1.3. The adrenocortical cell line NCI –H295R 
NCI H295R adrenocortical cells (figure 5) have been established in 1990 by Gazdar and 
colleagues as a continuous cell line originating from an adrenocortical carcinoma 
(Gazdar, et al., 1990). They have physiological characteristics of zonally undifferentiated 
human adrenal cortical cells and contain all essential enzymes involved in 
steroidogenesis of the adrenal, including those involved in mineralocorticoid, 
glucocorticoids, androgens and estrogen production. Most steroids of the adult adrenal 
cortex are produced in measurable amounts (Rainey, et al., 2004; Wang and Rainey, 
2012). NCI H295R cells are widely used in studies of steroidogenesis, including as part 
of in vitro test systems for assessing effects of endocrine disrupting chemicals, among 
numerous other applications (Gracia, et al., 2006; Muller-Vieira, et al., 2005; Ohlsson, et 
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al., 2010). In addition, NCI H295R cells have been characterized as a suitable in vitro 
model of hyperaldosteronism in various culture conditions, including static culture or 
spheroidal culture (Lichtenauer, et al., 2013).  
 
Figure 5: NCI H295R cells in static culture under a reverse phase microscope (x10). NCI 
H295R cells in image (A) and H295RA cells in image (B).  
Although NCI H295R adrenocortical cells express most of the enzymes involved in 
adrenal steroidogenesis, expression of CYP11B2 and associated production of 
aldosterone is minimal posing challenges for studies evaluating inhibitors of CYP11B2. 
Especially in culture conditions involving large amounts of culture medium dilution effects 
can lower aldosterone to non-detectable levels, despite NCI H295R being responsive to 
angII and potassium stimulation. Recently, Nanba and colleagues developed a 
melanocortin 2 receptor accessory protein transduced NCI H295R cell line (termed 
H295RA cells) that is responsive to ACTH and demonstrates increased aldosterone 
production (Nanba, et al., 2016).  
1.4. Chemical regulators of adrenal steroidogenesis 
Studies employing NCI H295R-derived cell lines as in vitro models investigated effects 
of endocrine-disrupting chemicals on adrenal steroids (Hecker, et al., 2006; Strajhar, et 
al., 2017) or characterized steroid biosynthetic pathway dynamics (Breen, et al., 2011b; 
Breen, et al., 2010; Mangelis, et al., 2016). Drugs can affect metabolic processes by 
either inhibiting enzymatic action of steroidogenic enzymes or by stimulating the 
production via intracellular molecular mechanisms. While enzyme inhibition is in most 
cases straight forward, stimulation is a complex process usually involving activation of 
many enzymes in a time-dependent manner and occurring in different phases (Bassett, 
et al., 2004; Rainey, et al., 2004).  
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A wide variety of substances have been shown to stimulate steroidogenesis in NCI 
H295R cells, including angII, forskolin, potassium and ACTH, the later presenting only a 
mild effect (Rainey, et al., 2004). AngII was selected based on its function as an effector 
molecule of the renin-angiotensin-aldosterone system (Szekeres, et al., 2009). Forskolin 
is a modifier of cortisol production, regulating steroid biosynthesis by increasing 
intracellular cAMP through activation of adenylate cyclase (Asif, et al., 2006; Cobb, et 
al., 1996; Watanabe and Nakajin, 2004).  
Abiraterone is a pregnenolone analogue used clinically to modulate androgen production 
in patients with prostate cancer (O'Donnell, et al., 2004). FAD is a non-steroidal 
reversible and competitive inhibitor (Steele, et al., 1987). It demonstrates inhibitory action 
against aromatases as well as CYP11B1 and CYP11B2. FAD has demonstrated poor 
selectivity regarding inhibition between CYP11B2 and CYP11B1, as opposed to its 
dextroenantiomer, FAD286 (Brunssen, et al., 2017; Weldon, et al., 2016). Metyrapone is 
a CYP11B1 inhibitor, which is frequently used as an agent for blocking adrenal 
steroidogenesis in adrenal disease, such as Cushing’s syndrome (Daniel, et al., 2015; 
Nieman, 2018), and was included in many in vitro studies of steroid metabolism (Breen, 
et al., 2011b; Fassnacht, et al., 2000).  
1.5. Computational mechanistic modelling of adrenal metabolism 
1.5.1.  Static cell culture models for characterizing pathway dynamics  
Assessments of adrenal disorders and how specific pathway interferences, therapeutic 
interventions and experimental manipulations affect steroidogenesis can benefit from 
approaches that characterize pathway dynamics. A mathematical modeling approach for 
this purpose is particularly suitable for the complex series of biochemical pathways that 
characterize steroidogenesis, and for which lesions affecting specific pathway 
components can lead to variable changes in steroid end-products. Mathematical 
description of biological networks, such as those involved in steroidogenesis, typically 
cannot be reduced to simple equations, but requires a system of non-linear differential 
equations with time dependent variables and many parameters that define the 
interactions and bonds of the system. The multi-parameter models can be utilized for 
simulating systemic behaviors in order to provide insight in metabolic processes. 
Additionally, optimization algorithms can produce parameter sets that describe those 
metabolic processes and thus helping in quantification of effects and alterations. 
Computational modeling holds the analytical strength to combine methods provided by 
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applied mathematics with experimental data (Scholma, et al., 2014), resulting not only in 
interpretation of scientific observations, but also in the design of experiments and 
research strategies.  
1.5.2.  Steady state as a tool for intracellular fluxes estimation 
Effects of drugs or other perturbations on steroidogenic pathways of NCI H295R cell-
lines have been commonly assessed by sampling culture medium at 24 and 48 hours 
after perturbations to the system. However, as we and others have shown (Breen, et al., 
2011b; Breen, et al., 2010; Mangelis, et al., 2016), there are several limitations to such 
experimental systems when applied to assess pathway dynamics. Notably the modeling 
procedures are demanding and necessitate large numbers of samples at different time 
points. The complexity of the aforementioned culture systems reflects the dynamic 
alterations in the culture environment such as cell growth, product formation and 
substrate utilization; metabolic steady state of the cell culture environment can eliminate 
these factors and simplify the modeling procedure.  
Benefits of metabolic steady state have been widely used in modelling, especially in 
metabolic engineering for optimization of production efficiency of bacteria. Techniques 
such as metabolic flux analysis (Toya, et al., 2011; Zamboni, et al., 2009)  or flux balance 
analysis (Edwards and Palsson, 2000; Kauffman, et al., 2003; Orth, et al., 2010) are 
based on the pseudo-steady state mass balance of intracellular metabolites. Under 
pseudo-steady state metabolite concentrations remain unchanged so that the rate of 
change of concentrations is near to zero, resulting in simplification of the equations and 
allowing for system solutions based on stoichiometric modeling. Combined with 
additional information gained from 13C-labeled tracers metabolic fluxes can be calculated 
even for highly complicated systems, such as the central carbon metabolism. This 
approach has been applied to mammalian cell culture, where the assumption of the 
pseudo-steady state allowed for metabolic flux analysis (Metallo, et al., 2009; Quek, et 
al., 2010). Nevertheless, metabolic steady state can also be approached when 
precursors of a metabolic system are constantly supplied. Associated difficulties of static 
culture in assessing pathway dynamics can be avoided using a flow-through system 
where culture medium is continuously supplied to achieve a steady state in substrate 
and product concentrations. Under such conditions, intracellular flux calculations are 
possible for relatively simple metabolic pathways and allow for evaluation of drug effects 
and other pathway perturbations.  
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2. Hypothesis and aims 
Aldosterone and cortisol excess are associated with the clinical conditions of primary 
aldosteronism and Cushing syndrome leading to dysregulation of blood pressure, 
immune function and metabolism with potentially severe pathological consequences 
(Bollag, 2014; Miller and Auchus, 2011; Newell-Price, et al., 2006). Aldosterone and 
cortisol are produced in different zones of the adrenal cortex by the respective enzymes, 
CYP11B2 and CYP11B1 (Bureik, et al., 2002). Drugs targeting the activity of these 
enzymes provide one strategy for treating primary aldosteronism or hypercortisolism 
when surgical intervention is not an option (Deinum, et al., 2015; Sanderson, 2006). 
Since CYP11B1 and CYP11B2 share 93% homology in their primary sequences there is 
need for development of highly selective drugs that target one of the two enzymes with 
minimal effect on the other. Associated with this there is also need for development of 
accurate and efficient in vitro assays for evaluating selectivity. Due to species differences 
in CYP11B1 and CYP11B2, such in vitro methods used for clinical applications ideally 
employ adrenal cortical cell homogenates from primates (Bogman, et al., 2017; Cerny, 
et al., 2015; Weldon, et al., 2016) or assays involving human NCI H295R adrenocortical 
cells (Hecker, et al., 2006; Hofland, et al., 2013; Winther, et al., 2013). 
The subject of this doctoral thesis is the development and evaluation of computational 
and modeling approaches for studying metabolic processes of steroid production in in 
vitro systems and humans.  
AIM I: Our first approach is the development of a computational mechanistic model 
constructed from mass balance and mass conservation equations that would 
successfully describe steroidogenesis over time. Utilizing this mechanistic model and 
based on our experimental data we evaluated steroidogenic processes in human adrenal 
cortical-derived NCI H295R cells under various perturbations (Mangelis, et al., 2016). 
AngII and forskolin were used as stimulators of steroidogenesis. In addition, we 
examined the effects of inhibition of CYP17 enzyme by abiraterone. We applied a 
computational analysis using this cell line to estimate model parameters for different 
conditions. Steroid production was assessed by liquid chromatography-tandem mass 
spectrometric (LC-MS)-based measurements of 10 steroids in cell culture incubates. To 
investigate whether our control model developed for steroidogenesis could adopt or 
reflect the physiological responses of NCI H295R cells, we tested our system against 
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angII and forskolin. In order to further test the model, we examined the effects of inhibition 
of CYP17 with abiraterone. 
AIM II: As outlined in the discussion of this thesis, despite the successful representation 
of steroidogenesis by our mechanistic model, certain limitations of ordinary time-
dependent differential equations (ODE) modelling have revealed the need for a simpler 
approach that would be more effective and easily reproducible. Therefore as a second 
step we developed a system based on cell culture under continuous medium flow that 
would allow the metabolic system to achieve steady state hence simplifying intracellular 
metabolic flux calculations (Mangelis, et al., 2018). To test the potential of our system 
we used a novel inhibitor of CYP11B2, SI_191. As negative controls we used fadrozole 
(FAD) and metyrapone (MET), two established and effective aromatase inhibitors with 
low selectivity for CYP11B1 and CYP11B2. We additionally examined the system’s 
ability to investigate wider effects in steroidogenic pathways using another novel 
pharmaceutical with inhibitory actions on CYP17, SI_254. 
AIM III: Steroid profiling in in vitro studies has been the basis of the two first parts of this 
dissertation. To further study the physiological function of steroids in humans, steroid 
profiles in plasma samples of healthy individuals were used in order to investigate 
dependencies of steroid values on population characteristics like age and gender. Our 
aim was the development of reference values of steroid plasma concentrations for a 
healthy population. For this, data from our clinical study described elsewhere 
(Eisenhofer, et al., 2017) were utilized and multivariable fractional polynomial modeling 
was applied to produce age and gender adjusted reference intervals.  
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3. Materials and methods 
3.1. Experimental overview 
3.1.1. Computational mechanistic modeling of steroid metabolism 
For analyzing steroidogenic metabolism in NCI H295R cells two approaches combining 
mathematical modeling and steroid profiling were employed; one utilizing static cell 
cultures and another cells under steady state flow. The first computational modeling 
approach included two separate experimental set-ups, each including a separate set of 
untreated cells (control set) (figure 6). First, angII (100 nM) (Sigma-Aldrich, Germany) 
and forskolin (10 μM) (Sigma-Aldrich, Germany) were used separately to stimulate 
aldosterone and cortisol production, respectively. Second, a competitive inhibitor of 
CYP17 activity, abiraterone (Santa Cruz Biotechnology, US) was used, at a 
concentration of 1 μM. Concentrations were chosen based on previous studies (Bassett, 
et al., 2004; Leighton, 2011; Rijk, et al., 2012; Watanabe and Nakajin, 2004).  
Cells were cultured in 24-well plates at 2x105 cells per well and incubated for 24 hours 
before 600 µl of fresh medium containing one of the above mentioned agents was added. 
This provided the zero time point for subsequent sample collections. Culture medium 
(600 µl) from each of six replicates were collected at seven different time points of 0, 2, 
6, 10, 24, 34 and 48 hours, and stored at -80 oC until LC-MS analysis was performed. A 
mathematical model based on mass balance equations was constructed assuming two 
separate compartments, the cell interior and exterior was implemented in the Jsim 
simulation environment. LC/MS-MS derived data from cell culture supernatants were 
used as input in the model, and model parameters were estimated using sensop 
optimization methods in Jsim (Butterworth, et al., 2013).   
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Figure 6: Work flow of the computational modelling approach of steroid metabolism. LC-
MS derived concentrations were used as data input in the implemented mass balance 
based mathematical model. The implementation of the produced ordinary differential 
equations (ODE) system in Jsim resulted in estimation of kinetic parameters.  
2 4  
 
3. 1. 2 A st e a d y st at e s y st e m f or i n vitr o e v al u ati o n of st er oi d o g e ni c 
p at h w a y d y n a mi c s  
F or t h e s e c o n d m o d eli n g a p pr o a c h w e c o m bi n e d c o nti n u o u s m e di u m fl o w c ell c ult ur e 
wit h li n e ar m o d eli n g t o e xtr a ct i ntr a c ell u l ar fl u x r at e s of st er oi d m et a b oli s m. T o t e st t h e 
effi ci e n c y of o ur s y st e m, t w o s e p ar at e e x p eri m e nt al s et -u p s  w er e u s e d , o n e wit h t h e  
C Y P 1 1 B 2 i n hi bit or s F A D, M E T a n d SI _ 1 9 1 a n d o n e wit h t h e  C Y P 1 7 i n hi bit or SI _ 2 5 4. 
T h e e st a bli s h e d ar o m at a s e i n hi bit or s M E T a n d F A D w er e b ot h s u p pli e d b y Si g m a -
Al dri c h, G er m a n y.  
T h e e st a bli s h e d ar o m at a s e i n hi bit or s, M E T a n d F A D, w er e s u p pli e d b y Si g m a -Al dri c h, 
G er m a n y a n d di s s ol v e d i n di m et h yl s ulf o xi d e.  T h e t w o n o v el st er oi d o g e ni c e n z y m e 
i n hi bit or s SI _ 1 9 1 ( 3-( 4-c y a n o -3 -fl u or o ph e n yl) -5 -( 1, 3-di o x ol a n -2 -yl) p yri di n e) a n d SI _ 2 5 4, 
w er e s y nt h e si z e d b y Dr. A n dr e a s S c hir b el  (D e p art m e nt of N u cl e ar M e di ci n e, U ni v er sit y 
H o s pit al W ür z b ur g, G er m a n y) . I n bri ef, SI _ 1 9 1 w a s pr e p ar e d i n t w o st e p s (fi g ur e 7 ), 
st arti n g wit h a n a ci d -c at al y z e d r e a c ti o n t o yi el d t h e di o x ol a n e, 3-br o m o -5 -( 1, 3-di o x ol a n -
2 -yl) p yri di n e ( H ert z o g-R o n e n, et al., 2 0 0 9) . T hi s i nt er m e di at e w a s u s e d i n a S u z u ki-
Mi y a ur a -c o u pli n g r e a cti o n. F or t hi s a s u s p e n si o n of 4 1 2 m g ( 2. 5 m m ol) 4 -c y a n o -3 -
fl u or o p h e n yl b or o ni c a ci d, 5 7 5 m g (2. 5 m m ol) 3 -br o m o -5 -( 1, 3-di o x ol a n -2 -yl) p yri di n e, 7 6 0 
m g ( 2. 7 5 m m ol) sil v er c ar b o n at e a n d 1 7 4 m g ( 0. 1 5 m m ol) t etr a ki s tri p h e n yl p h o s p hi n e 
p all a di u m i n 3 0 m L b e n z e n e w a s r efl u x e d o v er 2 d a y s.  
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Fi g ur e 7: S c h e m ati c r e pr e s e nt ati o n of c h e mi c al pr e p ar ati o n of st er oi d o g e ni c i n hi bit or 
SI _ 1 9 1. T h e c h e mi c al pr o c e s s c o n si st s of t w o st e p s, st arti n g wit h a n a ci d -c at al y z e d 
r e a cti o n of 3-br o m o p yri di n e -5 -c ar b o x al d e h y d e ( 1) a n d et h yl e n e gl y c ol ( 2) yi el di n g t h e 
di o x ol a n e, 3 -br o m o -5 -( 1, 3-di o x ol a n -2 -yl) p yri di n e ( 3). T hi s st e p w a s f oll o w e d b y a S u z u ki -
Mi y a ur a -c o u pli n g r e a cti o n i n v ol vi n g r e a cti n g t h e di o x ol a n e i n a s u s p e n si o n of 4 1 2 m g 
( 2. 5 m m ol) 4-c y a n o -3 -fl u or o p h e n yl b or o ni c a ci d ( 4).  
Aft er c o oli n g t o r o o m t e m p er at ur e t h e mi xt ur e w a s p o ur e d i nt o 1 0 0 m L w at er, e xtr a ct e d 
t hr e e ti m e s wit h 5 0 m L m et h yl-t ert-b ut yl et h er a n d dri e d o v er s o di u m s ulf at e. Aft er 
stri p pi n g t h e s ol v e nt t h e cr u d e pr o d u ct w a s p urifi e d b y c ol u m n c hr o m at o gr a p h y u si n g 
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CH2Cl2/MeOH 98/2 (vol/vol) as the eluent. The yield of a white solid was 43.5 mg (0.16 
mmol, 6.4%). 1H-NMR (CDCl3): δ = 8.82 (dd, 2H), 7.99 (t, 1H), 7.76 (m, 1H), 7.50 (m, 
2H), 5.93 (s, 1H), 4.13 (m, 4H). The novel, non-steroidal CYP17-inhibitor, SI_254, is 
subject to a patent application; thus, data about the synthesis and chemical structure of 
this compound will be available at a later date.  
A detailed description of the experiment is given further on paragraph 3.4.1. In short, a 
different substrain of NCI H295R cells termed H295RA cells were cultivated in enclosed 
culture chambers (µ-Slide, Ibidi) (figure 8). Constant medium flow was applied overnight 
allowing the cells to reach steady state, and the next day four initial hourly medium 
samples were collected (control samples), followed by fadrozole (10nM), MET (10 μM), 
SI_254 (100nM) or ASI_191 (5nM) induction for an additional four hours. Calculation of 
secretion rates was based on flow-through medium measurements of 11 steroids 
(pregnenolone, progesterone, corticosterone, 11-deoxycortisosterone, aldosterone, 
17OH-progesterone, 11-deoxycortisol, cortisol, DHEA, androstenedione, testosterone) 
utilizing LC-MS. Mathematical  computations allowed for estimation of steroid secretion 
rates and in a second step, intracellular flux rates and rate constant relative changes of 
steroid production thus enabling assessments of the selectivity of the inhibitors. 
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Figure 8: Work flow of the second modeling approach involving continuous flow culture 
system and linear modeling. 
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3.1.3 Calculation of age and gender adjusted reference intervals for 
plasma adrenal steroids for healthy population 
The third modeling approach involved steroid profiling of hypertensive and normotensive 
volunteers and utilization of plasma steroid values for reference intervals calculation of 
healthy population (figure 9). Steroid profiles of 8 steroids (pregnenolone, 11-
deoxycorticosterone, corticosterone, 17OH-progesterone, cortisone, 
dehydroepiandrosterone (DHEA), dehydroepiandrosterone-sulfate (DHEA-SO4) and 
androstenedione) were derived from LC/MS-MS concentrations in plasma of 525 
normotensive and hypertensive volunteers with (n=227) and without (n=298) 
hypertension.  
Additional information of age and gender was collected and utilized for extraction of age 
and gender adjusted reference intervals. Steroid data were used as input for the 
construction of fractional polynomials and for estimation of polynomial parameters and 
associated deviation. Fractional polynomial analysis was conducted in R Studio version 
0.99.082-2016 (R version 3.2.1, R Core Team, 2013, http://www.r-project.org/).  
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Figure 9: Work flow of the statistical modeling analysis for the extraction of 2,5% and 
97,5% reference interval for 8 steroids in patient plasma. LC/MS derived plasma steroid 
concentrations were used in multivariate fractional polynomial analysis for constructing 
age and gender dependent equations.    
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3.2 Liquid chromatography – tandem mass spectrometry 
Steroids in samples of culture medium were measured by liquid chromatography-tandem 
mass spectrometry using a previously described method (Peitzsch, et al., 2015). 
Measurable steroids in the panel included pregnenolone, progesterone, 11-
deoxycorticosterone, corticosterone, aldosterone, 17OH-progesterone, 
androstenedione, 11-deoxycortisol, DHEA, cortisol and testosterone. For sample 
preparation, incubates (500 μl) were loaded onto OASIS WCX-96 well plates from 
WATERS equilibrated with methanol (0.5 ml), water (0.5 ml) and 4% phosphoric acid. 
Samples were eluted into 96-deep well collection plates using positive pressure (207–
414 kPa) to facilitate passage of two passes of an isopropanol/methanol mixture (1:1). 
After drying under nitrogen at 40oC, reconstitution was achieved by addition of 100 μl 
mobile phase. 
3.3. Static cell culture mechanistic model 
3.3.1. Cell culture conditions 
Cells were cultured in Dulbecco's modified eagle medium and Ham’s F-12 medium (1:1) 
with L-glutamine and 15 mM HEPES (Invitrogen, Germany) supplemented with 2.5% NU 
serum (BD Biosciences, Germany), 1% Insulin-Transferrin-Selenium and 1% Pen/Strep 
antibiotics (Life technologies, Germany). Cells were incubated in a humidified chamber 
with 5% CO2 at 37 ◦C. To investigate proliferation and viability, cells (5x105) were seeded 
in 24-well plates in 6 replicate wells per treatment condition and incubated for 24 hours. 
Fresh medium containing either angII, forskolin or abiraterone was added after 24 hours 
of incubation and cells were collected at 0, 24 and 48 hours to be analyzed for cell 
number, cell diameter and viability using trypan blue staining and a Countess® 
Automated Cell Counter (Invitrogen, Germany). The measured average cell diameter, 
assuming a spherical shape with cellular circularity limited to 85%, was used to estimate 
the average single cell volume and the total initial volume of cells in all conditions.  
3.3.2. Computational model representation for steroid metabolism and 
cell proliferation using ODE systems 
In both stimulation and inhibition, we modeled control and treated conditions, based on 
experimental measurements, and compared the estimated rate constants of enzymatic 
reactions of treated conditions to control. As previously described (Breen, et al., 2011a; 
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Breen, et al., 2010), the model has two separate compartments: intracellular and 
extracellular (figure 10). In the present study, the parameter for intracellular cholesterol 
concentrations represents all various forms of cholesterol storage. Cholesterol import 
from the culture medium is considered to be a first-order, non-reversible process, since 
we assume no secretion of cholesterol from the cells. All other conversions from 
precursor steroids to products are described as first-order processes. For the analysis, 
we assumed that the adjustment to the stimulation and inhibition conditions is rapid and 
therefore all free parameters are constant. A model for cellular proliferation was included 
in order to estimate the volume of viable cells. Cell proliferation was assumed to exhibit 
exponential growth according to the equation: 
 
𝑁𝑐𝑒𝑙𝑙𝑠(𝑡) = 𝑁𝑐𝑒𝑙𝑙𝑠
𝑡=0 𝑒𝑘𝑝 𝑡   (1) 
 
We estimated the 𝑘𝑝 values using the least squares method for fitting averaged 
measured cell numbers at each time point in all treatments. These measurements 
agreed with the exponential function of the number of cells and allowed to determine the 
𝑘𝑝 values for each condition. Following this relation, the volume of the cells was defined 
as: 
 
 𝑉𝑐𝑒𝑙𝑙𝑠(𝑡) = 𝑉𝑐𝑒𝑙𝑙𝑠
𝑡=0 𝑒𝑘𝑝 𝑡   (2) 
 
The initial volume of the cells, 𝑽𝒄𝒆𝒍𝒍𝒔𝒕=𝟎 , was determined based on the initial number of viable 
cells and the single cell volume assuming spherical shape, and further used for 
estimation of time dependent concentrations of steroids in the mass balance equations.  
3.3.3. Metabolic pathways 
Steroid metabolic pathways can be described as a network of enzymatic reactions from 
cholesterol to steroid end-products (figure 10). The modeled pathway consists of 11 
steroids and 13 enzymatic reactions, catalyzed by eight different enzymes. Following the 
conversion of cholesterol, pregnenolone is then converted to product steroids in the 
endoplasmic reticulum and mitochondria (Payne and Hales, 2004). For all enzymatic 
reactions we assumed that the substrate is in instantaneous equilibrium with the complex 
under the Michaelis and Menten assumption and that the Michaelis constant is much 
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higher than the substrate concentration, so that the product formation is linearly 
increasing. 
 
 
Figure 10: Model representation of steroidogenesis: The cell interior and the culture 
medium are divided in two separate compartments. Metabolic reactions are described 
by rate constants (ki). Cholesterol is imported in the cells, transferred to mitochondria by 
the steroidogenic acute regulatory protein (StAR) and then converted to pregnenolone 
by the cholesterol side-chain cleavage enzyme (CYP11A1). The conversion of 
pregnenolone to the final products of the model involves many enzymes, 17α-
hydroxylase/17,20-lyase  (P450c17), 3β-hydroxysteroid dehydrogenase (3β-HSD), 21 
hydroxylase (CYP21A1), 11β-hydroxylase (CYP11B1) and aldosterone synthase 
(CYP11B2). Import and secretion of all steroids is presented by ratios, 𝑟𝑥 =  
𝑘+,𝑥
𝑘−,𝑥
. 
All enzymatic reactions are then described by first-order equations. Despite the fact that 
enzymatic reactions involve an intermediate step, we assumed that the initial phase of 
complex formation is rapid and that all metabolic reactions are in quasi-equilibrium 
condition. Thus, the conversion of substrates to products in the cells is given by the 
following equation: 
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𝑑[𝑉𝑐(t)𝐶𝑐,𝑥
 (𝑡)]
𝑑𝑡
=  𝑘𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛𝑉𝑐(𝑡)𝐶𝑐,𝑝𝑟𝑒𝑐𝑢𝑟𝑠𝑜𝑟
 (𝑡) − 𝑘𝑢𝑡𝑖𝑙𝑖𝑧𝑎𝑡𝑖𝑜𝑛𝑉𝑐(𝑡)𝐶𝑐,𝑥 
 (𝑡) 
+𝑘−,𝑥𝑉𝑚𝐶𝑚,𝑥
 (𝑡) − 𝑘+,𝑥𝑉𝑐(𝑡)𝐶𝑐,𝑥
 (𝑡)   (3) 
where 𝑉𝑐(𝑡) is the total cell volume and 𝐶𝑐,𝑥 (𝑡), 𝐶𝑐,𝑝𝑟𝑒𝑐𝑢𝑟𝑠𝑜𝑟 (𝑡) are the total concentrations 
of steroid x and the precursor of steroid x in the cells, respectively. 𝐶𝑚,𝑥 (𝑡) is the total 
concentration of steroid x in the culture medium, 𝑘𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛 and 𝑘𝑢𝑡𝑖𝑙𝑖𝑧𝑎𝑡𝑖𝑜𝑛, stand for rate 
constants of production and utilization reactions, while 𝑘−,𝑥 and 𝑘+,𝑥 are the import and 
secretion rates of each steroid.  
For the inhibition model, the effect of the CYP17 inhibitor abiraterone (Vasaitis, et al., 
2011), is represented by introducing four inhibition constants KI3, KI4, KI8 and KI9 
modifying the four respective enzymatic reactions catalyzed by CYP17 (see Figure 10), 
namely conversions of pregnenolone to 17OH-pregnenolone (KI3), progesterone to 
17OH-progesterone (KI8), 17OH-pregnenolone to DHEA (KI4) and 17OH-progesterone 
to androstenedione (KI9). During inhibition the effective equilibrium constant of the 
enzyme increases by a dimensionless factor,  𝐼𝑖𝑛 = 1 +
𝐶𝑖𝑛(𝑡)
𝐾𝐼𝑖𝑛
 , where 𝐶𝑖𝑛(𝑡) is the 
intracellular concentration and 𝐾𝐼𝑖𝑛 is the inhibition constant of the inhibitor, both 
measured in concentration units (M) (Keener and Sneyd, 2009). The rate constant of the 
reaction then decreases by the same factor. Hence, rate constants k03, k04, k08 and k09 
are divided by factors I3, I4, I8 and I9, respectively:   
 
    𝐼3 = 1 +
𝐶𝑎,𝑐(𝑡)
𝐾𝐼3
, 𝐼4 = 1 +
𝐶𝑎,𝑐(𝑡)
𝐾𝐼4
 , 𝐼8 = 1 +
𝐶𝑎,𝑐(𝑡)
𝐾𝐼8
  𝑎𝑛𝑑  𝐼9 = 1 +
𝐶𝑎,𝑐(𝑡)
𝐾𝐼9
 ,     (4) 
where 𝐶𝑎,𝑐(𝑡) is the abiraterone concentration in cells, causing modified rate constants 
for the inhibition model, 𝑘03𝑖𝑛 =
𝑘03
𝐼3
, 𝑘04𝑖𝑛 =
𝑘04
𝐼4
, 𝑘08𝑖𝑛 =
𝑘08
𝐼8
 and 𝑘09𝑖𝑛 =
𝑘09
𝐼9
. Thus, the 
abiraterone concentration 𝐶𝑎,𝑐(𝑡) reduces the rate constants of the respective inhibition 
sites, effectively inhibiting the corresponding pathways of steroid production. 
3.3.4. Transport processes 
A variety of transport mechanisms realizes the exchange of steroids between cells and 
medium (Maxfield and Wustner, 2002; Neufeld, et al., 1996). Due to low concentrations 
of the synthesized steroids in the cells throughout the experimental duration, it is unlikely 
that steroid exchange mechanisms were saturated, therefore we considered steroid 
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transport as a reversible first-order process. The exchange process for each steroid is 
then characterized by two rate constants, 𝑘−,𝑥 and 𝑘+,𝑥for import and secretion and thus 
the concentration of each steroid in the medium can be described as, 
 
𝑑[𝑉𝑚𝐶𝑚,𝑥(𝑡)]
𝑑𝑡
=  𝑘+,𝑥𝑉𝑐(𝑡)𝐶𝑐,𝑥(𝑡) − 𝑘−,𝑥𝑉𝑚(𝑡)𝐶𝑚,𝑥(𝑡)   (5)  
 
where 𝐶𝑚,𝑥(𝑡) and 𝐶𝑐,𝑥(𝑡) are the concentrations of steroid x in the medium and cells 
respectively. Our system of 26 differential equations was defined by 14 reaction rate 
constants for the intracellular metabolic pathways and 22 transport constants, resulting 
in a total of 36 parameters.   
For the inhibition model, we assumed lack of degradation through the 48 hours 
period for abiraterone treatment. Concentrations can then be described as, 
 
𝐶𝑎,𝑐(𝑡) = 𝑘𝑎𝐶𝑎,𝑚(𝑡)   (6) 
 
where 𝑘𝑎 is the equilibrium coefficient and 𝐶𝑎,𝑐(𝑡) and 𝐶𝑎,𝑚(𝑡) are the concentrations of 
abiraterone in the cells and medium, respectively, at any given time t. As previously 
described (Breen, et al., 2011a), the concentration of the inhibitor in the cells, 𝐶𝑎,𝑐(𝑡) is 
then calculated by solving the molecular balance equation, 
 
𝑉𝑐(𝑡)𝐶𝑎,𝑐(𝑡) + 𝑉𝑚𝐶𝑎,𝑚(𝑡) = 𝑉𝑐(0)𝐶𝑎,𝑐(0) + 𝑉𝑚𝐶𝑎,𝑚(0)   (7) 
 
and taking into account that equation (6) and 𝐶𝑎,𝑐(0) = 0 the following equation can be 
derived: 
 
𝐶𝑎,𝑐(𝑡) = (
𝑘𝑎
1+𝑘𝑎𝑉𝑐(𝑡) 𝑉𝑚⁄
) 𝐶𝑎,𝑚(0)   (8) 
 
A full system of equations for the control study of both metabolic and transport processes 
for each individual steroid is given as an example in Appendix A1. 
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3.3.5. Parameter estimation 
We conducted a separate, independent analysis for all above mentioned conditions 
using Jsim simulation software. Jsim is a java-based, open-source modeling system for 
data analysis, especially designed for model evaluation and fitting mathematical models 
to experimental data (Butterworth, et al., 2013). Jsim uses Mathematical Modeling 
Language (MML) and supports algorithms for solving ordinary and partial differential 
equations systems, as well as parameter optimization tools. Our system of 26 non-linear 
differential equations for cellular and medium concentrations was implemented with Jsim 
software as described in methods. An example of the code in Jsim used for estimation 
of the kinetic parameters of the control model is presented in Appendix A2.  
Compartment volumes, proliferation constants and number of cells were estimated as 
described above and were used as fixed parameters, while zero time point measured 
concentrations determined the initial input values for extracellular concentrations. We 
used literature values (Breen, et al., 2011a) as initial input values for intracellular 
concentrations, adjusted to the number of cells in this study. Reaction rate constants and 
secretion and import rates were free parameters throughout the analysis and were fitted 
to the mean steroid concentrations measured by liquid chromatography-tandem mass 
spectrometry.  
Jsim provides 8 different automated parameter optimization tools for minimizing the 
distance between data values and calculated model concentrations. For this particular 
analysis SENSOP, a weighted non-linear least squares optimizer for parameter fitting of 
data, was chosen as an advanced optimization method (Chan, et al., 1993). The main 
reason for applying SENSOP in this study is that it allows for estimating the variance of 
the data automatically, leading to corresponding scaling weights. Furthermore, it is a 
bounded optimizer, also supporting multiprocessing of a wide range of data (more 
algorithmic details are given in (Chan, et al., 1993)).  
Following the construction of the code and the import of experimental data in Jsim, 
parameter fitting was done semi-automatically using SENSOP optimizer by adjusting 
parameters sequentially for the three main production pathways. This procedure involved 
examination of parameter correlations and evaluation of parameter confidence ranges. 
Correlated parameters were appropriately fixed and the number of free parameters was 
reduced with each consecutive optimization, until final results were achieved. 
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3.4. Steady state model system for computation of pathway kinetics 
3.4.1. Cell culture conditions for continuous flow culture system 
Although NCI H295R adrenocortical cells express most of the enzymes involved in 
adrenal steroidogenesis (Strajhar, et al., 2017), expression of CYP11B2 and associated 
production of aldosterone is minimal posing challenges for studies of aldosterone 
synthase inhibitors. Recently Nanba and colleagues developed a melanocortin 2 
receptor accessory protein transduced NCI H295R cell line (termed H295RA cells) that 
is responsive to ACTH and demonstrates increased aldosterone production (Nanba, et 
al., 2016). We therefore used this cell line, which was generously provided by Dr William 
Rainey. Compared to NCI H295R cells, we confirmed that H295RA cells showed a 1.7-
fold increase in aldosterone levels at baseline and a 2.9-fold increase following ACTH 
stimulation. To further strengthen aldosterone production we used UltroserG, a serum 
supplement shown to elevate aldosterone levels in another NCI H295R substrain (Wang, 
et al., 2012). This treatment with use of the H295RA cell line resulted in adequate 
amounts of steroids for the requirements of our study.  
Four separate experimental set-ups were used, each including a separate continuous 
flow culture system tested with and without four different steroidogenic inhibitors. Cells 
were cultured in Dulbecco's modified eagle medium and Ham’s F-12 medium (1:1) with 
L-glutamine and 15 mM HEPES (Invitrogen, Germany) supplemented with 2.5% 
UltroserG serum substitute (Pall Biopharmaceuticals), 1% Insulin-Transferrin-Selenium 
and 1% Pen/Strep antibiotics (Life technologies, Germany), incubated in a humidified 
chamber under 5% CO2 at 37oC. 
Static cultures were used to test the proliferation and toxicity effects under control and 
treatment conditions. For this purpose, cells (2x106) were seeded in 6-well plates in six 
replicate wells (three separate experiments of two replicates) per treatment condition and 
incubated for 24 hours. Fresh medium containing FAD (10 nM), MET (10 μM), SI_191 (5 
nM) or SI_254 (100 nM) and equivalent volumes of vehicle (dimethyl sulfoxide) for control 
conditions were then added to the wells and cells were collected for analysis after 0, 24 
and 48 hours. Cell number and viability were determined using trypan blue staining and 
a Countess® Automated Cell Counter (Invitrogen, Germany).  
To achieve steady state for steroid production of H295RA cells, a culture system of 
continuous medium supply was developed (figure 11). For this, 4x106 cells were seeded 
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onto flat flow chambers (ibiTreat, μ-slide I0.8 Luer, Ibidi GmbH) and allowed to attach over 
24 hours. Two ibidi chambers connected in series were used in each set-up to increase 
steroid signal strengths.  
 
Figure 11: Schematic representation of the experimental set-up of the continuous 
medium flow cell culture system. Culture medium was supplied to the system via a 
syringe pump. Flowing medium was then perfused through the chambers and over the 
attached cells in the two combined chambers and finally collected in Eppendorf tubes for 
analysis.  
After attachment, continuous medium flow (𝑓 = 0.015 𝑚𝑙/𝑚𝑖𝑛) was applied overnight 
using a syringe pump (Fusion 200 Touch syringe pump, KR Analytical Ltd). After four 
hours the pumped medium was switched to include a steroidogenic pathway inhibitor 
and four additional hourly samples were collected. To define optimal concentrations for 
cell culture, literature values for FAD and MET (Breen, et al., 2011b; Breen, et al., 2010; 
Brunssen, et al., 2017) and a concentration range around previously derived 
experimental IC50 concentrations for SI_191 and SI_254 were evaluated. From this we 
established optimal concentrations for inhibitory actions of 10 nM, 10 μM, 5 nM and 100 
nM for FAD, MET, SI_191 and SI_254 respectively. All samples were stored at -20oC 
until measurement of steroid concentrations. 
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3.4.2 Steroid secretion rates and intracellular fluxes calculation under 
steady state conditions 
Adrenal steroid metabolic pathways form a network of processes starting from uptake or 
synthesis of cholesterol followed by conversion to pregnenolone and from there to other 
steroids (Fig. 12) (Hu, et al., 2010). Our modeling approach is based on mass balance 
and mass reaction equations, taking into account both the intracellular metabolic 
processes and the transport processes through the membrane, modified to meet the 
properties of a system under steady state (a detailed description of the derivation of the 
essential equations is provided in the supplementary material, appendix B1). The model 
included all measured steroids: pregnenolone, progesterone, 11-deoxycorticosterone, 
corticosterone, aldosterone, 17OH-progesterone, DHEA, androstenedione, 11-
deoxycortisol, cortisol and testosterone. Due to lack of data for 17OH-pregnenolone, the 
conversions of pregnenolone to DHEA and 17OH-progesterone were calculated as two 
separate reactions, without the intermediate conversion of pregnenolone to 17OH-
pregnenolone.  
Within the ibidi chamber the basic equation that describes the secretion of an individual 
steroid from the cells to the flow of the medium is: 
𝑉
𝑑𝐶𝑥
𝑑𝑡
= 𝐽𝑥 − 𝐹 ∙ 𝐶𝑥 (9) 
where, 𝑉 is the volume of the chamber, 𝐶𝑥 is the concentration of steroid x in the 
chamber, 𝐽𝑥 is the secretion rate of the steroid from the cells to the medium and 𝐹 is the 
flow of medium through the chamber. Under steady state conditions achieved by 
constant flow of medium all intracellular steroid concentrations can be assumed to 
remain unchanged over time so that the reduction rate 𝑑𝐶
𝑑𝑡
  is equal to zero for all steroids 
and therefore equation (9) transforms to: 
𝐽𝑥 = 𝐹 ∙ 𝐶𝑥 (10) 
Concentrations 𝐶𝑥 were extracted as mean values of the measured steroid 
concentrations at the respective time points for control and inhibition in all conditions, 
allowing for the calculation of the secretion rates of all steroids. Secretion rates for all 11 
measured steroids were calculated based on eq. (10). 
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Figure 12: Model representation of H295RA steroid production: cells and culture medium 
are compartmentalized in two different areas, the cell interior and exterior, separated 
from the cell membrane. As a first step external cholesterol is absorbed from the cells 
and converted to pregnenolone via the cholesterol side-chain cleavage enzyme 
(CYP11A1), which is in turn converted to all the following adrenal steroids. In our 
experimental set-ups we used the steroidogenic inhibitors FAD, MET and SI_191 of 
aldosterone synthase (CYP11B2) and 11β-hydroxylase (CYP11B1) and SI_254 of 17α-
hydroxylase (CYP17). All precursor to product conversions correspond to the enzymatic 
reactions and are noted by the respective flux rates (vik).  
 
Steroid concentrations under steady state remain unchanged and intracellular fluxes and 
secretion rates of steroids are connected through linear equations around the system’s 
nodes (steroids): 
∑ influxes = ∑ effluxes + 𝐽𝑥 (11) 
Following the estimation of steroid secretion rates, all calculated rates where used as an 
input to the produced system of linear equations for the estimation of intracellular fluxes. 
This approach is only possible for downstream reactions due to the simple linear 
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conversions, where each steroid is converted from a single precursor to a single product. 
Therefore the above methodology applies to 9 of the measured steroids (progesterone, 
11-deoxycorticosterone, corticosterone, aldosterone, 17OH-progesterone, 
androstenedione, 11-deoxycortisol, cortisol and testosterone) and the outlined system 
contains six equations including the intracellular fluxes and secretion rates as variables 
(supplementary material B7, Table 1). The mathematical derivation of the analytical 
solution for the steady state model and all the equations describing steroid production 
are given in appendixes B1 and B2. 
Upstream steroids are connected via more complicated reactions since many can 
convert to or originate from more than one steroid, thus producing an under-determined 
system of equations. The complexity of the upstream region of adrenal steroidogenesis 
requires additional modeling applications. To further investigate effects in upstream 
steroidogenic pathways, we applied a quadratic programing modeling approach to allow 
for estimation of fluxes of the upstream pathways. The quadratic programing model 
involves the solution of the following equation: 
𝐴 ∙ 𝑣 = 𝑦 (12) 
where A is the stoichiometric matrix based on the aforementioned equations for all 11 
steroids, v is the matrix containing all involved fluxes (subject to constrains that all fluxes 
are positive,  𝑣 ≥ 0) and y is the vector constructed from the measured secretion rates 
(appendix B3).  
Since our system has more unknown variables than equations, it is underdetermined and 
solving it requires an optimization method that minimizes the p-norm || … ||p of the linear 
system, where p is a positive integer: 
𝑚𝑖𝑛 ‖𝐴𝑣 − 𝑦‖𝑝,     𝑣 ≥ 0        (13) 
In order to find the optimal solution, we applied the CVXOPT algorithm (M. S. Andersen, 
2012) (version 1.2.2,  2018) in PYTHON 2.7 under the Spyder 3.2.3 programming 
environment. CVXOPT is a python software package for convex optimization that 
requires a positive semidefinite quadratic programming formulation. We applied the 
CVXOPT algorithm to the data for all our four experimental set-ups. The set of fluxes 
which resulted from the CVXOPT optimization method where tested against the data 
derived from the analytical model and also against other python solvers.  
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The calculated set of flux rates further allowed for the derivation of relative changes in 
the rate constants of enzymatic reactions. Although direct calculations of rate constants 
could not be achieved since this requires estimations of available amounts of precursor, 
an estimation of relative changes of rate constants was instead derived from estimated 
secretion rates of precursors and fluxes of products. Relative changes in rate constants 
were used for further characterizations of the inhibitory effects of the drugs. A detailed 
description of the quadratic programming solution and method for calculating changes in 
rate constants is explained in the supplementary material, appendixes B3 and B4 and 
the implementation of the method and the aforementioned calculations is presented in 
appendix B5. Changes in rate constants for conversions of 17OH-pregnenolone to DHEA 
and to 17OH-progesterone as well as cholesterol to pregnenolone were not calculated 
due to lack of data for concentrations of precursor or intermediate steroids for these 
steps.  
3.4.3 Statistical analysis 
All results are provided as means ± standard deviations of measured concentrations of 
replicate samples. Data were analyzed and mean concentrations of the four hourly 
samples before and after induction of substances were compared using paired t-tests in 
PYTHON 2.7 under the Spyder 3.2.3 programming environment and the module “stats” 
of the scipy statistical package. Where statistical significance is indicated in the text, this 
reflected P-values of less than 0.05. 
3.5. Regression and classification models for diagnostic clinical studies 
3.5.1. Age and sex adjusted reference intervals for adrenal steroids in 
plasma – patient data collection 
Subjects included 525 normotensive and hypertensive volunteers, all providing written 
informed consent under a clinical protocol approved by the local Ethics committee that 
allowed for collection of data and banking of biological specimens for purposes of 
comparisons to patient populations and establishment of reference intervals for new 
diagnostic tests. Blood sampling was carried between 8:00-10:00 am following overnight 
fasting before sampling, which was carried out after at least 20 minutes of supine rest. 
Heparinized blood samples were kept chilled and centrifuged within 2 hours of collection 
to separate plasma, which was stored at -80oC until assayed by LC-MS/MS according to 
an established method (Peitzsch, et al., 2015). Analyzed steroids included 
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pregnenolone, 11-deoxycorticosterone, corticosterone, 17OH-progesterone, cortisone, 
dehydroepiandrosterone (DHEA), dehydroepiandrosterone-sulfate (DHEA-SO4) and 
androstenedione. 
3.5.2. Mathematical description of multivariate fractional polynomial 
analysis 
Reference intervals of 2.5 and 97.5 percentile for the above mentioned steroids were 
constructed as a function of age and gender using multivariate fractional polynomial 
analyses (Franscini, et al., 2015; Royston, et al., 1999; Royston and Wright, 1998). This 
mathematical approach involves two separate fittings of mean  𝜇(𝑎𝑔𝑒) and standard 
deviation  𝜎(𝑎𝑔𝑒), both variables dependent on the patient’s age. First stage involves 
independent fitting of the fractional polynomials to the mean and standard deviation. The 
fractional polynomials are determined in this step by minimization of the model deviance. 
In the second step, weighted linear regression is utilized for estimation of the best-fit 
polynomial coefficients that describe the fractional polynomial. 
Before initiating the fractional polynomial fitting procedure for age-specific reference 
intervals, plasma concentrations were first normalized by logarithmic, square root or x2 
transformation, with age transformed in all cases according to the formula below 
described by Royston and Wright (Royston and Wright, 1998). 
 
Xage = e
log(0.01)∙(Age−min(Age))
(max(Age)−min(Age))         (14) 
 
Following normalization, steroid concentrations were grouped according to age. Average 
values and standard deviations of the groups were then used for an independent fitting 
of polynomial models, which allowed estimation of best-fit polynomial coefficients 
(Franscini, et al., 2015). Reference curves of the nth percentile of each steroid were then 
calculated according to the below formula 
 
yn = Mn(Age) +  SDn(Age) ∙ Φ
−1 (
n
100
)        (15) 
 
where Φ-1 is the inverse of the standard normal distribution, Mn (Age) is the mean and 
SDn (age) the standard deviation of the age groups. Due to the fact that both age and yn 
are transformed and must be reversed to the original scale, the formulae produced by 
the method become overly complex. To simplify, we calculated the 2.5% and 97.5% 
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percentiles for all patients according to the estimated yn functions and subsequently fitted 
a regression line to the derived percentile values, which were then used as the reference 
interval curves. Fractional polynomial analysis was conducted using R Studio version 
0.99.082-2016 (R version 3.2.1, R Core Team, 2013, http://www.r-project.org/). Curve 
fitting of percentile equations was carried out and percentile plots were prepared using 
the Matlab Curve fitting toolbox (3.5.1 2015) in Matlab (version R2015a). 
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4. Results 
4.1. Computational analysis of steroid profiling in NCI H295R cells 
As described in paragraph 3.1.1, static cell culture of NCI H295R cells was employed for 
generating data as input to a computational modelling approach of adrenal steroid 
metabolism (figure 6). Τhis involved two experimental set-ups, one stimulating the cells 
with angII (100 nM) and forskolin (10μM) and one inhibiting CYP17 with abiraterone (1 
μΜ). Rate constants of the intracellular enzymatic reactions and equilibrium constants of 
the steroid transport through the membrane were then estimated by a Jsim based 
mathematical implementation of steroidogenesis.  
4.1.1. Transport and metabolic pathway modeling 
Measured concentrations of steroids in culture medium of the two separate experimental 
set-ups were used to approximate parameters for modeling transport and metabolic 
pathways. Raw data for experimental measurements and calculated secretion rates are 
displayed in appendix A3, Tables 1-2 and Tables 3-4, respectively. In all conditions the 
average percentage of viable cells was approximately 91.0 ± 2.7 % (mean ± SD) (A5, 
figure 1) and the mean cell diameter 10.8 ± 0.9 μm (mean ± SD). Assuming a spherical 
shape, this indicated an average single cell volume of 659.8 μm3 and provided the total 
initial volume of cells. Modeled curves of predicted concentrations were then compared 
with the measured concentrations showing close correspondence for untreated cells 
(control), as reflected by a root mean square error (RMSE) [sum of the mean squared 
difference of data and model values] of 3.4 (figure 13 and A5, figure 2A).   
 
4.1.2. Angiotensin II and forskolin stimulation 
Treatment with angII led to an increase in concentrations of aldosterone and aldosterone 
precursor steroids in cell culture medium relative to the control. The precursor steroids, 
pregnenolone, progesterone, and 11-deoxycorticosterone showed peak increases at 6 
to 20 hours, whereas aldosterone concentrations continued to increase throughout the 
48-hour period of sample collection (figure 13). After treatment with angII, the model 
accurately predicted mean measured concentrations of 17OH-progesterone, 11-
deoxycorticosterone, 11-deoxycortisol, androstenedione, corticosterone and cortisol, as 
reflected by an RMSE of 4.3. The model underestimated concentrations of aldosterone 
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compared to experimental data at 6, 10 and 24 hours. Model curves for pregnenolone 
and progesterone also showed minor discrepancies compared with experimental data at 
24 and 34 hours. Treatment with forskolin resulted in larger increases in all steroids 
except for aldosterone compared to angiotensin (figure 13). Increases in precursor 
steroids peaked between 10 and 24 hours. In contrast, cortisol, aldosterone and 
androstenedione did not reach their maximum by 48 hours.  
 
 
Figure 13: Medium concentrations of nine steroids (pregnenolone, progesterone, 17OH-
progesterone, corticosterone, 11-deoxycorticosterone, androstenedione, aldosterone, 
cortisol and 11-deoxycortisol) in untreated cells (control) (●), with angII (▪) and forskolin 
(◊) stimulation. Data points for all seven time points of 0, 2, 6, 10, 24, 34 and 48 hours 
are presented as mean concentrations in nM ± SD. In the same graphs, model generated 
curves are plotted for each condition, control (straight blue line), angiotensin (dashed 
green line) and forskolin (dots and dashes red line). 
Model predicted concentrations showed overall concordance with experimental data as 
reflected by an RMSE of 3.1. Modeled curves for pregnenolone and progesterone 
overestimated measured concentrations at 24 and 34 hours, whereas curves for 
aldosterone underestimated measured values at 6, 10 and 24 hours. Comparisons of 
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steroid concentrations of angII and forskolin treatments to those of untreated cells 
revealed two distinct time-dependent phases in the dynamics of induced changes in 
steroid production (figure 14). First, an increase in precursor steroids during the initial 6 
hours was observed, peaking at 6 to 12 hours and returning to baseline concentrations 
at approximately 24 hours. The second phase involving an increase of product steroids 
started 12 hours after stimulation and reached its maximum at 48 hours. 
    
 
Figure 14: Percentage of change of measured steroid concentrations under stimulating 
conditions compared to untreated cells. A: Cortisol and its precursors with forskolin 
stimulation. B: Aldosterone and its precursors, with angII stimulation. 
Reaction rate constants of enzymatic reactions (see figure 10) involved in aldosterone 
production (k02, k05, k10, k12 and k14) were all increased after angII stimulation compared 
to control (Table 1). In contrast, rate constants for reactions of the cortisol pathway (k03, 
k06, k11 and k13) showed no or negligible changes after angII treatment. Comparisons of 
model parameters between forskolin and control conditions indicated increases in rate 
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constants of enzymatic reactions leading to production of cortisol (k02, k03, k06, k08, k11 
and k13).  Rate constants for conversion of 17OH-pregnelonone to DHEA (k04) and 17OH-
progesterone to androstenedione (k09) were also increased after forskolin, whereas rate 
constants for reactions of the aldosterone pathway (k05, k10, k12 and k14) did not change 
or were decreased. 
  
Table 1. Estimated rate constants for control, angiotensin II and forskolin 
 Control Angiotensin II Forskolin Units 
k01 0.0092 0.270 0.037 hr-1 
k02 0.129 0.240 0.559 hr-1 
k03 2.176 2.626 2.549 hr-1 
k04 1.628 1.371 3.763 hr-1 
k05 1.478 1.612 0.746 hr-1 
k06 10.345 10.700 11.242 hr-1 
k07 10.539 10.541 6.102 hr-1 
k08 1.11 1.473 2.582 hr-1 
k09 0.394 0.133 0.533 hr-1 
k10 2.349 3.166 2.330 hr-1 
k11 13.167 13.094 14.131 hr-1 
k12 0.573 0.824 0.530 hr-1 
k13 0.805 0.805 1.520 hr-1 
k14 0.183 0.327 0.115 hr-1 
kp 0.018 0.022 0.017 hr-1 
Table 1: Estimated parameters of the first study involving angII and forskolin stimulation. 
Rate constants of the intracellular metabolic network are presented for each condition in 
hr-1. 
 
4.1.3. Abiraterone treatment 
Modeled concentration curves for untreated cells (control) in experiments involving 
blockade of CYP17 with abiraterone presented with overall close fits to the experimental 
data, as indicated by an RMSE of 3.1 (figure 15 and A3, figure 2B). The modeled curve 
for aldosterone showed the greatest discrepancy compared with the experimental data, 
particularly at 10, 24 and 34 hours.  
 
Treatment with abiraterone led to increases in concentrations of the aldosterone 
precursors, progesterone, 11-deoxycorticosterone and corticosterone relative to control 
conditions (figure 15). In contrast, steroids downstream of CYP17 (17OH-progesterone, 
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11-deoxycortisol, androstenedione, cortisol and DHEA) showed reductions in measured 
concentrations relative to control.  
 
 
Figure 15: Concentrations of nine steroids in the medium (pregnenolone, progesterone, 
17OH-progesterone, corticosterone, 11-deoxycorticosterone, androstenedione, 
aldosterone, cortisol and 11-deoxycortisol) measured at seven times points (0, 2, 6, 10, 
24, 34 and 48 hours) in untreated cells (control) (●) and with abiraterone inhibition (▪), 
presented as mean concentrations in nM ± SE. Model generated curves are plotted as 
functions of time for each condition, control (straight line) and abiraterone inhibition 
(dashed line). 
Modeled curves accurately predicted measured concentrations for progesterone, 11-
deoxycorticosterone, androstenedione, cortisol and DHEA, as reflected by an RMSE of 
4.8. Pregnenolone was overestimated at 24 and 34 hours and underestimated at 48 
hours, while aldosterone was underestimated at 10, 24 and 34 hours. Rate constants of 
enzymatic reactions catalyzed by CYP17 (k03, k04, k08 and k09) were reduced after 
abiraterone treatment compared to the control model (Table 2). Rate constants for the 
conversion of DHEA to androstenedione (k07) and of 11-deoxycortisol to cortisol (k13) 
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were also decreased, whereas rate constants involved in reactions of the aldosterone 
pathway displayed no or only minor changes. 
  
Table 2. Estimated rate constants for control and abiraterone 
 Control Abiraterone Units 
k01 0.015 0.011 hr-1 
k02 0.089 0.112 hr-1 
k03 2.140 1.496 hr-1 
k04 1.645 0.934 hr-1 
k05 1.500 1.500 hr-1 
k06 10.343 10.343 hr-1 
k07 10.539 0.052 hr-1 
k08 1.079 0.875 hr-1 
k09 0.412 0.255 hr-1 
k10 2.350 2.346 hr-1 
k11 13.165 13.164 hr-1 
k12 0.645 0.608 hr-1 
k13 1.200 0.643 hr-1 
k14 0.189 0.177 hr-1 
kp 0.018 0.015 hr-1 
 
Table 2: Estimated parameters of the second study involving abiraterone inhibition. Rate 
constants of the intracellular metabolic network are presented for each condition in hr-1. 
4.2. Steady state model for in vitro evaluation of steroidogenic pathway 
dynamics 
4.2.1. Continuous flow culture steroid profiling 
A second experimental setup (paragraph 3.1.2.) was evaluated in order to improve 
experimental conditions and address limitations of the analytical, computational mass 
balance approach. For this, a continuous culture system was combined with linear 
modelling and quadratic programming in order to estimate intracellular flux rates and 
relative changes in rate constants of the steroidogenic reactions. LC/MS derived 
concentrations were analysed and further used to calculate steroid secretions rates from 
the cells to the flowing medium. In a second step, flux rates and changes in the rate 
constants were calculated and used to evaluate the inhibitory effects of FAD, MET, 
SI_191 and SI_254 on steroidogenesis.   
For all drug treatments, the inhibitory effects of agents on steroid secretion were 
immediately apparent within the first hour of perfused administration. Following treatment 
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with FAD, aldosterone, corticosterone and cortisol showed respective decreases 
(P<0.001) of 49%, 21% and 36%, whereas there were increases (P<0.001) in 11-
deoxycortisol, and 11-deoxycorticosterone (figure 16). Similarly in MET treated cells, 
aldosterone, corticosterone and cortisol showed respective decreases of 62% (P<0.001), 
46% (P<0.05) and 53% (P<0.001), 11-deoxycorticosterone showed an increase, but 11-
deoxycortisol showed no significant change. Concentrations of progesterone and 
testosterone increased (P<0.001) after treatment with FAD and MET, whereas 
pregnenolone, androstenedione, DHEA and 17-hydroxprogesterone remained 
unchanged or showed less than a 20% change from pretreatment values. 
(Supplementary material B7, figure 1). Treatment with SI_191 resulted in a 70% 
reduction (p<0.001) in aldosterone concentrations compared to pretreatment values, 
while cortisol and corticosterone were reduced (P<0.001) by 23% and 26% respectively 
(Fig. 4). In contrast, 11-deoxycortisol and 11-deoxycorticosterone increased (P<0.01) by 
61% to 70% respectively after treatment with SI_191 (figure 16).  
In contrast to the pattern of results for the other three agents, treatment with SI_254 
caused significant increases in steroids of the mineralocorticoid biosynthetic pathway 
and decreases in steroids of the glucocorticoid pathway (figure 16). Specifically, 
aldosterone, corticosterone and 11-deoxycorticosterone were respectively increased 
(P<0.001) by 155%, 201% and 169%, whereas concentrations of both11-deoxycortisol 
and cortisol were decreased (P<0.001) by 36%. For both SI_191 and SI_254, 
concentrations of pregnenolone, DHEA, 17OH-progesterone, progesterone and 
testosterone showed no or less than 20% changes compared to the control values 
(Supplementary material B7, figure 2).  
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Figure 16: Mean continuous flow medium concentrations and standard deviation of 
aldosterone, corticosterone, cortisol, 11-deoxycortisol and 11-deoxycorticosterone under 
FAD (10nM), MET (10μM), SI_191 (5nM) and SI_254 (100nM) treatment. Inhibitors were 
induced after the fourth hour of culture (time of induction indicated by the dotted line).  
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4.2.2. Secretion rates, intracellular flux rates and relative changes in rate 
constants 
Rates of steroid secretion under pre- and post-treatment conditions (Table 3), estimated 
according to the flow of medium, provided the basis for calculations of intracellular fluxes 
of enzymatic reactions (as illustrated in appendix B1, figure 1) in accordance with the 
mathematical model outlined in the methods section. In addition to those mathematical 
formulations, a detailed example of analytical flux rate calculations is provided in 
appendix B6. Quadratic programming allowed for calculation of the upstream pathway 
fluxes as well as the relative changes in rate constants of the reactions. Changes in 
fluxes before and after treatment with FAD or MET (Supplementary material B7, Table 
2) or before and after treatment with SI_191 or SI_254 (Supplementary material B7, 
Table 3) generally paralleled changes in rates of steroid secretion (Table 3). 
After treatment with FAD, the rates of conversion (fluxes) of 11-deoxycorticosterone to 
corticosterone (v13), corticosterone to aldosterone (v14) and 11-deoxycortisol to cortisol 
(v23) and were reduced respectively by 29%, 51% and 39% compared to pretreatment 
values (Table 2). Treatment with MET resulted in reductions of 52% for v13, 62% for v14 
and 53% for v23, overall larger than those for FAD. Nevertheless, from comparisons of 
changes in rate constants, treatment with FAD showed a near 2-fold larger impact than 
MET on the rate constant (k14) for catalytic steps of CYP11B2 downstream of the initial 
11βOH-lase step. 
Treatment with SI_191 indicated more selectivity of this compound for inhibition of 
CYP11B2 compared to both FAD and MET (Table 4). Specifically SI_191 resulted in a 
60% decrease in the rate constant (k14) for conversion of corticosterone to aldosterone 
compared to 35% and 18% respective decreases for this step after FAD and MET. In 
contrast, for the initial 11β-hydroxylase step involving conversion of 11-
deoxycorticosterone to corticosterone, decreases in rate constants differed only 
marginally between 51% and 63% for the three drugs. Similarly for the 11β-hydroxylase-
catalyzed conversion of 11-deoxycortisol to cortisol, decreases in rates constants also 
differed from 49% to 60%. 
As a consequence of the larger impact of SI_191 than FAD and MET on catalytic steps 
of CYP11B2 downstream of 11β-hydroxylase, the impact on overall catalytic activity of 
CYP11B2 indicated a 82±6.8% reduction in combined rate constants (k13 & k14) for 
conversion of 11-deoxycorticosterone to aldosterone after SI_191 compared to 
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respective 66.5±9.3% and 69.9±3.3% decreases after FAD and MET. Due to these and 
other differences impacting CYP11B1 the 70% fall in aldosterone production after SI_191 
was 3-fold larger than the 23% fall in cortisol production. This compared to only slightly 
larger falls in aldosterone compared to cortisol production after FAD (50% vs 39%) and 
MET (67% versus 53%). 
 
  
Table 3: Mean secretion rates and standard deviation of all steroids as calculated from 
LC-MS/MS measured concentrations in [pmol/min] for all treatments. Black arrows 
▼and▲ next to the values indicate the reduction or increase of the secretion rate under 
treatment compared to the control.  
 
control FAD control MET
aldosterone 0.006  ± 0.000 0.003  ± 0.001 ▼ 0.015  ± 0.003 0.005  ± 0.001 ▼
corticosterone 0.033  ± 0.007 0.025  ± 0.006 ▼ 0.036  ± 0.004 0.019  ± 0.009 ▼
cortisol 0.873  ± 0.108 0.532  ± 0.118 ▼ 0.594  ± 0.058 0.277  ± 0.047 ▼
11-deoxycortisol 0.573  ± 0.064 0.866  ± 0.160 ▲ 0.657  ± 0.022 0.606  ± 0.078 ▼
11-deoxycorticosterone 0.096  ± 0.014 0.140  ± 0.011 ▲ 0.141  ± 0.017 0.175  ± 0.018 ▲
pregnenolone 0.050  ± 0.012 0.057  ± 0.006 ▲ 0.031  ± 0.008 0.029  ± 0.008 ▼
androstenedione 0.097  ± 0.006 0.115  ± 0.011 ▲ 0.060  ± 0.013 0.063  ± 0.011 ▲
DHEA 0.052  ± 0.042 0.042  ± 0.031 ▼ 0.045  ± 0.028 0.043  ± 0.028 ▼
17OH-progesterone 0.027  ± 0.003 0.029  ± 0.003 ▲ 0.016  ± 0.002 0.013  ± 0.002 ▼
progesterone 0.005  ± 0.000 0.010  ± 0.001 ▲ 0.006  ± 0.001 0.010  ± 0.002 ▲
testosterone 0.114  ± 0.006 0.160  ± 0.005 ▲ 0.073  ± 0.006 0.139  ± 0.014 ▲
control SI_191 control SI_254
aldosterone 0.010 ± 0.000 0.003 ± 0.000 ▼ 0.004  ± 0.000 0.011  ± 0.001 ▲
corticosterone 0.016 ± 0.001 0.014 ± 0.001 ▼ 0.023  ± 0.001 0.070  ± 0.002 ▲
cortisol 0.637 ± 0.011 0.484 ± 0.016 ▼ 0.730  ± 0.019 0.467  ± 0.027 ▼
11-deoxycortisol 0.537 ± 0.029 0.853 ± 0.105 ▲ 1.240  ± 0.028 0.799  ± 0.044 ▼
11-deoxycorticosterone 0.085 ± 0.004 0.144 ± 0.034 ▲ 0.245  ± 0.021 0.660  ± 0.021 ▲
pregnenolone 0.125 ± 0.013 0.116 ± 0.018 ▼ 0.141  ± 0.002 0.158  ± 0.005 ▲
androstenedione 0.030 ± 0.005 0.050 ± 0.010 ▲ 0.085  ± 0.011 0.069  ± 0.003 ▼
DHEA 0.062 ± 0.011 0.068 ± 0.015 ▼ 0.061  ± 0.002 0.060  ± 0.002 ▼
17OH-progesterone 0.011 ± 0.001 0.012 ± 0.002 ▲ 0.017  ± 0.001 0.013  ± 0.000 ▼
progesterone 0.007 ± 0.001 0.010 ± 0.002 ▼ 0.008  ± 0.001 0.012  ± 0.001 ▼
testosterone 0.054 ± 0.003 0.088 ± 0.014 ▲ 0.100  ± 0.009 0.121  ± 0.006 ▲
Steroid
Steroid secretion average rates in pmol/min ± SD
ChangeFAD METSteroid
SI_254
Change
ChangeChangeSI_191
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For SI_191 drops in rate constants were restricted to steps catalyzed by CYP11B1 and 
CYP11B2, whereas for MET and FAD there appeared to be additional smaller inhibitory 
impacts on CYP21A2 and 17α-hydroxylase. For steps with increased fluxes there were 
occasional isolated increases in rate constants. 
The 17alpha-hydroxylase inhibitor, SI_254, produced as expected a selective 61% drop 
in the rate constant for conversion of progesterone to 17OH-progesterone (Table 4). 
Rates of conversion of progesterone to 11-deoxycorticosterone (v12), 11-
deoxycorticosterone to corticosterone (v13) and corticosterone to aldosterone (v14) were 
all increased due to blockade of that step and channeling of steroidogenesis to the 
mineralocorticoid pathway. Rates of conversion of 17OH-progesterone to 11-
deoxycortisol (v22) and of 11-deoxycortisol to cortisol (v23) were decreased due to 
blockade of upstream production of 17OH-progesterone and 17OH-pregnenolone and 
associated with negligible impacts on rate constants. 
4.2.3. Cell number and viability 
Cell number and viability, assessed under static culture conditions, indicated no cytotoxic 
effects of any of the investigated compounds at the dose concentrations used for studies 
of pathway dynamics (Supplementary material, Fig. 3 and 4). Viability was estimated 
between 90-96%. There were also no significant changes in proliferation in the absence 
or presence of each of the four investigated compounds. 
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Percent changes in fluxes and rate constants of enzymatic reactions 
Enzymatic steps and enzymes FAD MET SI_191 SI_254 
cholesterol → pregnenolone 
CYP11A1 
flux v01 2.8 ± 4.1  -17.3 ± 8.6  17.7 ± 11.1  -7.9 ± 5.4  
rate constant k01 n.a. n.a. n.a. n.a. 
pregnenolone → progesterone 
3β-HSD 
flux v11 3.1 ± 4.2  -17.5 ± 9.1  22.4 ± 11.6  1.8 ± 5.1  
rate constant k11 -10.6 ± 18.9 -13.8 ± 15.1 28.5 ± 6.5 -2.2 ± 2.2 
progesterone → 11-deoxycorticosterone 
CYP21A2 
flux v12 25.0 ± 9.9  4.9 ± 11.2  41.8 ± 27.6  173.1 ± 
16.1  
rate constant k12 -33.7 ± 10.6  -32.9 ± 10.0  -0.7 ± 19.4  78.4 ± 8.9 
11-deoxycorticosterone → corticosterone 
CYP11B1/CYP11B2 
flux v13 -29.1 ± 7.6  -52.4 ± 15.3  -40.9 ± 2.5  194.1 ± 
13.7  
rate constant k13 -51.0 ± 9.5  -61.9 ± 12.3  -63.1 ± 10.0  8.5 ± 6.6 
corticosterone → aldosterone 
CYP11B2 
flux v14 -50.5 ± 11.3  -62.6 ± 2.6  -70.1 ± 3.0  155.4 ± 
17.9  
rate constant k14 -34.9 ± 11.6 -17.7 ± 25.3 -59.5 ± 5.3 -15.3 ± 4.0 
pregnenolone → DHEA 
CYP17(17α-hydroxylase 
and 17,20 lyase) 
flux v31 18.7 ± 10.7  31.6 ± 11.3  28.7 ± 18.2  0.5 ± 5.9  
rate constant k31 2.1 ± 18.0 38.2 ± 25.4 34.2 ± 5.3 -10.6 ± 3.2 
progesterone → 17-hydroxyprogesterone 
CYP17(17α-hydroxylase) 
flux vv1 -0.9 ± 4.1  -24.3 ± 8.8  18.8 ± 9.3  -40.2 ± 4.8  
rate constant kvv1 -47.5 ± 7.7 -51.6 ± 7.1 -14.5 ± 19.9 -60.8 ± 4.5 
pregnenolone → 17-hydroxyprogesterone 
3β-HSD 
flux v21 -2.3 ± 3.8  -27.2 ± 9.2  13.5 ± 9.0  -26.6 ± 6.2  
rate constant k21 n.a. n.a. n.a. n.a. 
17-hydroxyprogesterone → 11-deoxycortisol 
CYP21A2 
flux v22 -3.6 ± 4.0  -29.2 ± 9.4  15.1 ± 8.8  -35.6 ± 5.5  
rate constant k22 -10.6 ± 5.4  -14.0 ± 9.7  5.7 ± 3.8  -16.2 ± 3.5 
11-deoxycortisol → cortisol 
CYP11B1 
flux v23 -39.2 ± 2.9  -53.3 ± 5.9  -23.1 ± 3.0  -35.8 ± 6.2  
rate constant k23 -59.5 ± 2.5  -49.4 ± 3.0  -51.6 ± 3.8  -0.7 ± 2.7 
17-hydroxyprogesterone → androstenedione 
CYP17(17,20 lyase) 
flux vv2 30.1 ± 8.4  55.4 ± 16.5  59.1 ± 23.0  6.6 ± 8.3  
rate constant kvv2 20.3 ± 3.5 49.0 ± 17.8 45.1 ± 9.8 38.9 ± 8.5 
DHEA → androstenedione 
3β-HSD 
flux v32 32.0 ± 8.0  51.3 ± 16.8  71.1 ± 24.1  1.1 ± 9.3  
rate constant k32 62.2 ± 21.3  91.5 ± 
114.2  73.4 ± 9.2  1.2 ± 11.2 
androstenedione → testosterone 
17β-HSD 
flux v33 40.9 ± 8.8  90.7 ± 20.8  72.5 ± 32.4  21.5 ± 11.3  
rate constant k33 17.8 ± 1.7  81.1 ± 16.8  9.4 ± 16.4  47.9 ± 6.1 
Table 4: Estimated percent difference of fluxes and relative rate constant changes in all 
treatments compared to control, presented as mean percentage and standard deviation. 
Each flux and rate constant change corresponds to a conversion of a precursor steroid 
to a product and the respective enzymatic reaction, as indicated in the table. 
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4.3. Reference intervals for adrenal steroid plasma concentrations 
Our third modeling approach involved the development of reference interval equations 
of 2.5% and 97.5% percentiles as a function of age and gender. As mentioned in 
paragraph 3.1.3, LC/MS measured steroid plasma concentrations of 525 hypertensive 
and normotensive volunteers were normalized and utilized for polynomial fitting for 
extraction of reference interval equations.  
Plasma concentrations of pregnenolone, androstenedione, DHEA, DHEA-SO4, 
cortisone, corticosterone and 11-deoxycorticosterone indicated a clear dependence of 
the steroids to age and gender and the development of age-specific reference intervals 
for these seven steroids. 17OH-progesterone in males indicated a relationship with age 
requiring age-specific reference intervals, whereas menstrual cycle status had to be 
considered for females.  
Multivariable fractional polynomial analysis on each steroid resulted in calculation of 
polynomial coefficients with standard errors (SE) of fractional polynomials following fitting 
of the models to means and standard deviations (SD) for steroid plasma concentrations 
(Supplementary material C, tables 1 and 2). Based on the estimated coefficients, age 
and gender adjusted equations for the lower and upper cut-offs (99.5% reference 
intervals) were developed (Table 5).  
Some steroids like 17OH-progesterone and 11-deoxycorticosterone demonstrated 
particularly low plasma concentrations, which were under the detection limits. For these 
steroids, only upper cut-offs were established. For 11-deoxycorticosterone and cortisone 
in both genders, 17OH-progesterone and androstenedione in males and corticosterone 
and pregnenolone in females the fractional polynomials values derived from the 
multivariate fractional polynomial fitting showed peaks around 20 years of age (figures 
17-20). 
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Table 5. Reference intervals equations for 8 steroids adjusted for age and 
gender 
Males (nmol/L) 
  Lower cut-off Upper cut-off 
17OH-progesterone 0.89 𝑦 = −0.08 ∙ 𝑥 + 9.42 
Pregnenolone y = 9124∙x−2.643 + 1.17 y = 57.1·e-0.028∙x 
Androstenedione y = -0.003∙x+1.69 y = 60.82∙x−0.766 + 3.68 
DHEA y = 18.13·e-0.036∙x y = 93.71·e-0.025∙x 
DHEA-S04 y = 7.55·e-0.032∙x y = -0.07·x+12.43 
Cortisone y = 1545∙x−1.64 + 27.9 y = 122.2∙e-0.007∙x 
Corticosterone y = 3.06∙x−0.22 y = 546.6∙x−0.801 
11-Deoxycorticosterone – y = 2.85∙x−0.533 
Females (nmol/L) 
  Lower cut-off Upper cut-off 
17OH-progesterone 0.24 6.84 
Pregnenolone y = 495.2∙x−1.538 y = 1138∙x−1.188 
Androstenedione y = 3.53·e-0.027∙x y = 13.92·e-0.017∙x 
DHEA y = 9.71·e-0.028∙x y = 84.49·e-0.025∙x 
DHEA-S04 y = -0.02·x+1.99 y = -0.002∙x2 + 0.12∙x+6.11 
Cortisone y = 1445∙x−1.31 + 17.12 y =386.8 ∙x−0.43 
Corticosterone y = 3.57∙x−0.195 y = 43120∙x−1.92 
11-Deoxycorticosterone – y = 0.65·e-0.0122∙x 
  
Table 5: All references intervals are in nmol/L except for DHEA-SO4, which is in µmol/L. 
17OH-progesterone age specific cut-offs were estimated for males only. For 
pregnenolone, androstenedione, DHEA, DHEA-SO4, cortisone, corticosteroone and 11-
deoxycorticosterone gender-specific cut-offs are shown by formulae that relate the cut-
off value (y) to age (x). 
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According to the fitted lines, 97.5 percentiles for pregnenolone ranged from 19.3 and 
21.4 nmol/L in respective 20-year old females and males down to 6.9 nmol/L in both 80-
year old females and males (figure 17).  
 
Figure 17: Panel of two steroid plasma concentrations of androstenedione (subfigures A 
and B) and pregnenolone (subfigures C and D). The black dots represent measured 
steroid plasma concentrations of males and black triangles of females. The white circles 
show the cut-offs calculated by multivariable fractional polynomial analysis for each year 
of age in all graphs and the dotted lines are the equations of the 99.5% reference 
intervals as a function of age, as shown in the legends of the graphs.  
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Similarly, 97.5 percentiles for respective females and males dropped precipitously over 
the 20 to 80 year age range from 9.3 and 10.2 nmol/L to 4.5 and 4.7 nmol/L for 
androstenedione, from 44.7 and 51.3 nmol/L down to 7.4 and 10.8 nmol/L for DHEA and 
from 8,753 and 14,115 nmol/L to 3,293 and 6,075 nmol/L for DHEA-SO4 (figure 18). 
 
Figure 18: Panel of two steroid plasma concentrations of DHEA (subfigures A and B) and 
DHEAS (subfigures C and D). The black dots represent measured steroid plasma 
concentrations of males and black triangles of females. The white circles show the cut-
offs calculated by multivariable fractional polynomial analysis for each year of age in all 
graphs and the dotted lines are the equations of the 99.5% reference intervals as a 
function of age, as shown in the legends of the graphs.  
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97.5% percentiles for corticosterone for females showed a greater discrepancy than 
those of males, while 11-deoxycorticosterone showed similar trends for both genders 
(figure 19).  
 
 
Figure 19: Panel of two steroid plasma concentrations of corticosterone (subfigures A 
and B) and 11-deoxycorticosterone (subfigures C and D). The black dots represent 
measured steroid plasma concentrations of males and black triangles of females. The 
white circles show the cut-offs calculated by multivariable fractional polynomial analysis 
for each year of age in all graphs and the dotted lines are the equations of the 99.5% 
reference intervals as a function of age, as shown in the legends of the graphs.  
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17OH-progesterone showed a linear correlation of the cut-offs with age in males, while 
pre- and post-menopause status had to be taken into account for females (figure20).  
 
 
Figure 20: Panel of two steroid plasma concentrations of cortisone (subfigures A and B) 
and 17OH-progesterone (subfigures C and D). The black dots represent measured 
steroid plasma concentrations of males and black triangles of females. The white circles 
show the cut-offs calculated by multivariable fractional polynomial analysis for each year 
of age in all graphs and the dotted lines are the equations of the 99.5% reference 
intervals as a function of age, as shown in the legends of the graphs.  
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5. Discussion 
Adrenal steroid hormones are responsible for regulating a variety of physiological 
functions such as salt balance, stress responses and metabolic processes. Excess of 
adrenal hormones such as aldosterone or cortisol is associated with clinical conditions 
impacting metabolic, cardiovascular and immune function. The homology of 93% shared 
by the aldosterone and cortisol producing enzymes, CYP11B2 and CYP11B1, dictates 
the need for highly selective drugs for pharmacological treatment of aldosterone and 
cortisol related diseases. Computational and regression models describing steroid 
metabolism based on experimental data, can improve understanding of intracellular 
mechanisms and stimulatory responses and contribute to investigating effects of 
endocrine-disrupting chemicals, drugs and gene manipulations. In this thesis, 
computational and regression models are applied to steroidogenesis in order to develop 
techniques supporting basic and clinical research.  
 
As a first approach, a static culture model system based on mass balance and mass 
reaction equations was used to kinetically evaluate adrenal steroidogenesis in human 
adrenal cortex-derived NCI H295R cells. Using well-known steroidogenic modulators, it 
was demonstrated that computational modeling of steroid pathways in adrenal cortical 
cells provides a useful tool for estimating changes in metabolic reactions associated with 
perturbations of steroidogenesis. In previous efforts of Breen et al (Breen, et al., 2011a; 
Breen, et al., 2010), a quasi-equilibrium model for describing steroidogenesis was 
established for basic cell culture conditions and the estimation of model parameters was 
based on measurements of intracellular and extracellular steroid concentrations. In order 
to simplify the experimental procedure for assays that measure extracellular steroid 
concentrations, a technique for describing steroidogenesis exclusively based on steroid 
measurements in cell culture incubates was developed, a method suitable for high-
throughput screening assays. Importantly, this procedure using NCI H295R cells can 
enable calculation of rate constants for reactions of steroidogenic pathways as indicated 
by expected changes after treatment with angiotensin II, forskolin and abiraterone. 
 
Angiotensin II stimulation is known to act in two phases (Bassett, et al., 2004; Rainey, et 
al., 2004). The first few hours after stimulation are characterized by increases in 
production of aldosterone precursors. This is followed by activation of aldosterone 
synthase leading to an increase in aldosterone. Our findings are consistent with this 
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sequence. Angiotensin II treated cells showed increased production of precursor steroids 
starting at 2 hours after treatment with a peak at 6 to 12 hours followed by increased 
aldosterone production. Furthermore, it was demonstrated that stimulation of 
steroidogenesis by forskolin follows a similar pattern to angiotensin II, but with an 
expected larger impact on cortisol and androgen pathways (Rainey, et al., 2004). This is 
in line with previous studies that showed forskolin-induced expression of enzymes 
involved in cortisol and androgen production (Asif, et al., 2006).  For forskolin treatment, 
this model indicated increases in rate constants for reactions in cortisol and androgen 
production pathways, but no changes or reductions for aldosterone pathways, as 
expected from the known actions of forskolin (Asif, et al., 2006; Cobb, et al., 1996). 
Observed changes in the estimated rate constants of enzymatic steps after treatment 
with angiotensin II were also consistent with the well-established action of this peptide to 
specifically target the aldosterone production pathway (Szekeres, et al., 2009).  
 
CYP11A1, or cholesterol side chain cleavage enzyme (P450scc), is responsible for 
conversion of cholesterol to pregnenolone at the inner mitochondria membrane (Miller, 
2013). This rate limiting step in steroid production defines the acute steroidogenic 
response to stimuli (Hu, et al., 2010), triggered by e.g. angiotensin II and forskolin. 
Shortly after stimulation increased amounts of cholesterol are cleaved by CYP11A1 at 
the inner mitochondrial membrane, leading to increased formation of pregnenolone. The 
results of the model are consistent with this mechanism, as reflected by a 2 to 4-fold 
increase of the rate constant, k02, during incubation with angiotensin II and forskolin 
compared to controls. This indicates an increased rate of cholesterol to pregnenolone 
conversion through CYP11A1 activity under both treatment conditions. In contrast, 
similar values for k02 were calculated during treatment with abiraterone compared to 
control, indicating as expected little change in the activity of CYP11A1 during inhibition 
of downstream steroidogenic pathways.  
 
When investigating metabolic processes of biological systems, estimations of reaction 
rate constants provide the ideal means to assess the activity of a process, independent 
of amounts of the specific reaction precursor. Rates of such processes reflect the product 
of the rate constant and available precursor, but it is the rate constant that is essential 
for evaluating underlying changes in the activity of a biological process. This includes 
evaluation of changes in amounts of functional enzymes or transporters, or perturbations 
in activity induced by a drug or a mutation. With abiraterone an average reduction of 25% 
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was demonstrated in the rate constants of the reactions catalysed by 17-alpha-
hydroxylase (k03 and k08) and a 40% reduction for those of 17,20-lyase (k04 and k09). 
Interestingly, the rate constant k07, representing conversion of DHEA to androstenedione 
by the enzyme 3-beta-hydroxysteroid dehydrogenase (3β-HSD), displayed a larger 
decrease than that for CYP17. This is in agreement with a study establishing that 
abiraterone also acts as an inhibitor of 3β-HSD-mediated conversion of DHEA to 
androstenedione (Li, et al., 2012). Lack of effect on 3β-HSD at other steps in 
steroidogenesis may be   caused by the inhibitory actions of abiraterone on 3β-HSD and 
concentrations of different substrates at each step (i.e., DHEA is produced in much lower 
concentrations compared to the substrates pregnenolone and 17-
hydroxypregnenolone). 
 
NCI H295R cells represent a commonly used in vitro system for assessing the impact of 
drugs and substances, such as environmental endocrine disrupters, on steroidogenesis 
(Hecker, et al., 2006; Hilscherova, et al., 2004; Rijk, et al., 2012). While some studies 
measured steroids at single time points (Cherradi, et al., 2001; Cobb, et al., 1996; Wang 
and Rainey, 2012; Xing, et al., 2011), others collected multiple time points (Le Roy, et 
al., 2000; Szekeres, et al., 2009; Wenzel, et al., 2009). Most of these studies involved 
measurements of a single or a limited number of steroids. Single time point analysis does 
not allow for examination of time-dependent changes, which as it shown here vary 
between different steroid metabolites. Time course evaluation thus highlights the 
advantage of steroid profiling with multiple time measurements to comprehensively 
assess alterations of steroidogenic pathways and rate processes. Interpretation of such 
data of static cultures, however, demands the application of a complex, mass balance 
oriented computational analysis. 
 
Both the concordance of modeled curves with experimental data and the findings of 
expected changes in rate constants illustrate that this computational analysis can be 
used to evaluate changes in steroidogenesis in NCI H295R cells. Some limitations of the 
model predictions are related to pregnenolone and aldosterone production, which 
showed some discrepancy from the experimental data. Pregnenolone is the product of 
the initial step in steroid synthesis and is subject to greater variability compared to other 
steroids, a limitation also described by Breen et al (Breen, et al., 2011a; Breen, et al., 
2010) in their computational modeling study of steroidogenesis using the same cell line. 
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According to the first-order enzyme kinetics used in the construction of the model, this 
limitation may reduce the accuracy of predicted concentrations and rate constants.  
Despite the successful assessments of steroidogenic pathway dynamics, the 
deterministic, multi-time point model displayed additional limitations mainly resulting from 
the nature of static cell culture systems. Such modelling approaches can be 
mathematically implemented by complex systems of ordinary differential equations 
primarily required due to the time dependency of static culture concentrations. The 
resulting large number of parameters for the definition of system interactions adds 
complications to the modeling, such as large parameter variation. In addition, 
probabilistic models must be applied to evaluate uniqueness of the estimated parameter 
(reaction rate constants) sets and variability of parameter values, further increasing the 
complexity of the method. In summary, static culture systems involve constantly 
changing precursor-product relationships necessitating multi-sampling time points and 
separate controls for each time point and experimental condition, hence increasing the 
variability between measurements and complicating interpretation. Consequently, such 
non-steady state culture systems require significant amounts of samples, consumables 
and computing time for simulating solutions and are therefore not generally practical for 
purposes of drug screening or for modeling of complex metabolic pathways. 
A second modeling approach for steroid metabolism was developed based on a steady 
state culture system, addressing the aforementioned limitations through procedures 
involving cell culture under constant flow of medium combined with mathematical 
modeling of steroidogenesis based on mass balance and mass action equations. In 
contrast to static culture systems, a constant flow steady-state system allows for cells to 
be used as their own controls. The resulting reduction in variation between control and 
experimental conditions is useful for determining effects of pharmacological inhibitors, 
particularly when using the H295R cell line, which is known to exhibit considerable 
behavioural variability. This system, as shown experimentally, enables assessments of 
less than one hour to establish inhibitory effects on steroid production according to 
estimated intracellular fluxes. It provides a novel method for assessing steroidogenic 
pathway metabolism, as it offers a useful in vitro tool for evaluating the selectivity of 
drugs, such as aldosterone synthase inhibitors, targeting steroidogenic pathway 
components. The system provides not only a simplified experimental procedure, but also 
a more comprehensive mathematical approach for examining the kinetics of intracellular 
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steroidogenesis. More generally the system may have relevance to other cell line models 
for investigating different metabolic pathways. 
Although enabling near direct calculation of intracellular fluxes for steroid metabolism, it 
is important to appreciate that changes in fluxes can reflect both changes in catalytic 
activity and amounts of available substrate. It is therefore crucial in pharmacological 
studies to include assessments of changing rate constants for catalytic steps. This is 
illustrated by the actions of SI_254 on 17α-hydroxylase. It decreases fluxes downstream 
of 17α-hydroxylase and increases fluxes through the mineralocorticoid pathway, but the 
inhibitory action was identified to be specific to the rate constant for the 17α-hydroxylase 
step. Similarly, enhanced selectivity of SI_191 over FAD and MET for inhibition of 
CYP11B2 was attributed to the considerably larger impact of SI_191 on rate constants 
rather than fluxes for conversion of corticosterone to aldosterone. Drug-associated 
increases in rate constants for some steps that paralleled increases in fluxes may reflect 
substrate-mediated enzyme activation. 
As with most models, this steady state-based approach is not without limitations. These 
include limited potential to account for the compartmentalized nature of steroid 
production as well as the centripetal arrangement of steroid producing cells within the 
three zones of the adrenal cortex [34, 35]. The NCI H295R cell line also does not 
recapitulate the phenotypic features of adrenal cortical cells from these three zones, but 
there are few alternatives for human cells. Additionally, not all of the main pathway 
steroids were measured leading to some fluxes and rate constant changes not being 
calculated and others being underestimated. 
Further refinements of the model could address some of the above limitations. Additional 
measurements of 18-hydroxycorticosterone would enable separate examination of 18-
hydroxylase and 18-methyloxidase catalytic activities of CYP11B2, useful for 
development of more selective inhibitors of aldosterone synthase. Measurements of 18-
oxocortisol and 18-hydroxycortisol could also be included in the mathematical model to 
obtain improved understanding of the sources and conditions leading to the production 
of these hybrid steroids in some patients with primary aldosteronism [4, 35]. Although 
co-expression of CYP11B1 and CYP11B2, as found in the H295RA cell line, is atypical 
for normal adrenal cortical cells, this co-expression is potentially useful for studies 
involving production of hybrid steroids. For studies of aldosterone synthase inhibitors, 
this co-expression also enables direct comparisons of selectivity for CYP11B2 over 
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CYP11B1 without concern for extraneous influences impacting cell systems that 
separately express these enzymes. 
The flow-through cell culture system could be adapted for co-culturing different cell lines 
(e.g. with different expression patterns of steroidogenic enzymes), allowing for series 
perfusion of cells analogous to the centripetal perfusion of the adrenal cortical zones 
[34]. Using perfusion with exogenous 13C-labeled steroids and pharmacological 
targeting of transport and enzymatic processes, it might be possible to gain improved 
insight into the compartmentalized nature of steroidogenesis.  
Apart from studying effects of pharmacological agents on steroidogenic pathways, 
measurements of rate constants and the dynamics of biological processes can also be 
useful for examination of perturbations resulting from genetic alterations. Such 
alterations not only include mutations directly impacting steroidogenic enzymes (Krone 
and Arlt, 2009; Miller, 2012; Miller and Auchus, 2011; Tiosano, et al., 2008), but also 
upstream calcium-signalling pathways now increasingly recognized to play important 
roles in development of adrenal cortical tumours (Beuschlein, et al., 2013; Monticone, et 
al., 2015; Williams, et al., 2014) 
Primary aldosteronism, the most common cause of secondary hypertension, results from 
dysregulated aldosterone production from one or both adrenals (Vaidya and Dluhy, 
2000). When involving one adrenal, effective treatment can usually be achieved by 
adrenalectomy. However, when involving both adrenals, representing the presentation 
in at least half of all affected patients, first-line therapy depends on use of 
mineralocorticoid receptor (MR) antagonists (Deinum, et al., 2015; Sica, 2015). Side 
effects and requirements for escalating doses represent problems for these medications. 
MR antagonists also do not protect from pathological MR-independent effects of high 
circulating concentrations of aldosterone (Monticone, et al., 2018), presumably 
explaining the high risk of cardiometabolic events and death in patients with primary 
aldosteronism treated with MR antagonists compared to other hypertensive patients 
(Hundemer, et al., 2018). 
The aforementioned considerations emphasize the need for alternative therapies to MR 
antagonists that can actually mitigate the toxic effect of high levels of circulating 
aldosterone. To this end aldosterone synthase inhibitors, have emerged as a viable 
alternative (Deinum, et al., 2015). Such inhibitors include LCI699 and FAD286, the latter, 
a dextroenantiomer of fadrozole, was also examined during this thesis (Azizi, et al., 
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2013). In concordance with previous studies (Breen, et al., 2011b; Brunssen, et al., 
2017), FAD demonstrated poor selectivity for CYP11B2 compared to CYP11B1. MET 
demonstrated similarly low selectivity, particularly for the conversion of corticosterone to 
aldosterone. Lack of increase in precursor steroids can be explained by MET-induced 
CYP11A1 inhibition (Wang, et al., 2012), as reflected by the 17% reduction in formation 
of pregnenolone (v01). Additional non-specific inhibitory actions of MET and FAD on 
17α-hydroxylase, as reflected by 47-52% decreases in rate constants for this step (kvv1), 
are in agreement with previous findings (Strushkevich, et al., 2013) (Fleseriu and 
Castinetti, 2016). In contrast, inhibitory actions on CYP21A2-catalyzed conversion of 
progesterone to 11-deoxycorticosterone (k12) do not appear to have been previously 
described. 
The overall higher selectivity of SI_191 over MET and FAD for CYP11B2 not only reflects 
enhanced inhibitory actions on aldosterone synthase downstream of the 11-beta-
hydroxylase step, but also lack of impact on other enzymes such as 17α-hydroxylase 
(kvv1) or CYP21A2-catalyzed conversion of progesterone to 11-deoxycorticosterone 
(k12). These findings emphasize the importance of establishing the selectivity of 
inhibitors by considering rate constants of multiple steps. For establishing the selectivity 
for CYB11B2 versus CYP11B1, it is particularly important to separately consider the 11-
beta-hydroxylase step common to both enzymes versus the downstream 18-hydroxylase 
and 18-methyloxidase steps specific to CYP11B2. Although SI_191 mediated inhibition 
of 11-beta-hydroxylase limits its selectivity for CYP11B2, by focusing drug development 
on downstream catalytic steps more selective inhibitors of aldosterone synthase might 
emerge. 
In contrast to CYP11B2, inhibitors of CYP17, such as abiraterone acetate, are used for 
treatment of castration-resistant prostate cancer (Bedoya and Mitsiades, 2012; Yin and 
Hu, 2014). In this study, the inhibitory actions SI_254 on CYP17 were apparent due to 
greatly reduced flux downstream of CYP17, the increased flux through upstream 
pathways and the redirection of precursor steroids towards the mineralocorticoid 
pathway. SI_254 may therefore have potential therapeutic use in treatment of castration-
resistant prostate cancer.  
The third mathematical approach applied in this thesis contributed to investigations of 
steroid profiles in humans. This study includes steroid plasma concentrations of 
normotensive and hypertensive patients, describing distributions of 8 steroids according 
to gender and age of patients. More specifically regression modelling has been applied 
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to plasma concentrations of pregnenolone, DHEA, DHEA-SO4, androstenedione, 17-
hydroxyprogesterone, cortisone, corticosterone and 11-deoxycorticosterone, providing 
equations that result in the 97.5 and 2.5 percentiles of the steroids for all specific ages 
between 18 and 81 years of age. 
Reference intervals are widely used for establishing normal ranges in a plethora of 
clinical measurements (Royston and Wright, 1998).  These data, as in this study, usually 
originate from patients characterized as healthy and therefore all values outside the 
extracted references will be considered abnormal and can contain information related to 
non-physiological function or disease. Reference ranges have also been established for 
steroids like aldosterone, cortisol and testosterone, but this is not generalized to all 
steroids since many are not described in the literature or are only measured by 
immunoassays. Despite the known and established correlation of many adrenal steroids 
to both gender and age, little has been done for describing the exact relationships and 
defining functions that correlate the steroid values to the individual’s age and gender. In 
this study, the age and gender dependency for the above mentioned steroids is 
established in addition to the fact that all the examined steroids displayed a negative 
correlation to age in both genders, with concentrations in males being higher than 
females for most steroids. As expected (Fanelli, et al., 2011), 17-alpha-
hydroxyprogesterone demonstrated a different distribution of reference intervals for 
females compared to males due to menopause, showing a sharp fall at the age of 53 
years and thus requiring application of a step function. 
In many cases the distribution of the fractional polynomial produced values revealed a 
peak of these steroids around 21 years of age, suggesting lower concentrations in 
younger ages. This is in agreement with previous studies demonstrating that steroids 
such as corticosterone, cortisone, androstenedione, DHEA and 17-alpha-
hydroxyprogesterone do not show negative correlation to age in childhood and 
adolescence (Kulle, et al., 2013; Kyriakopoulou, et al., 2013). In contrast to the fall in 
plasma concentrations for ages 21 to 70 years, these steroids increase generally during 
childhood showing highly altering dynamics in steroid distribution over age.  
In summary, both of the in vitro computational approaches applied in this thesis were 
successful in describing changes in steroidogenic enzymatic reactions. The deterministic 
model developed by multi-time point collections of medium from static cell culture 
systems allowed for assessments of steroidogenic pathway dynamics, including 
estimation of rate constants of enzymatic reactions. Limitations of the model, as outlined 
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above, led to the development of a continuous flow cell culture system for studying 
metabolic alterations, such as inhibitory effects of agents on steroidogenic pathway 
enzymes. This methodology establishes a more realistic model than that of static culture 
for investigating drug effects by both culturing cells under perfusion and using cells as 
their own controls. The system provides for simple and rapid calculation of secretion 
rates and intracellular fluxes and therefore offers a robust method for drug screening and 
investigation of metabolic mechanisms in vitro. The present thesis has contributed to in 
vitro (Mangelis, et al., 2016; Mangelis, et al., 2018) and diagnostic studies (Eisenhofer, 
et al., 2017) by providing computational and regression modelling means for 
investigating mechanisms of adrenal disorders and for further development of disease 
treatment.  
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Appendix A – Static culture model 
A1. ODE system equations of the static culture model 
 
Cholesterol: 
𝑑[𝑉𝑐(t)𝐶𝑐,𝑐ℎ𝑜𝑙𝑒𝑠𝑡𝑒𝑟𝑜𝑙
 (𝑡)]
𝑑𝑡
=  𝑘01𝑉𝑚𝐶𝑚,𝑐ℎ𝑜𝑙𝑒𝑠𝑡𝑒𝑟𝑜𝑙
 (𝑡) −  𝑘02𝑉𝑐(𝑡)𝐶𝑐,𝑐ℎ𝑜𝑙𝑒𝑠𝑡𝑒𝑟𝑜𝑙 
 (𝑡) 
𝑑[𝑉𝑚𝐶𝑚,𝑐ℎ𝑜𝑙𝑒𝑠𝑡𝑒𝑟𝑜𝑙(𝑡)]
𝑑𝑡
=  −𝑘01𝑉𝑚(𝑡)𝐶𝑚,𝑐ℎ𝑜𝑙𝑒𝑠𝑡𝑒𝑟𝑜𝑙(𝑡) 
 
Pregnenolone: 
𝑑[𝑉𝑐(t)𝐶𝑐,pregnenolone
 (𝑡)]
𝑑𝑡
=  𝑘02𝑉𝑐(𝑡)𝐶𝑐,𝑐ℎ𝑜𝑙𝑒𝑠𝑡𝑒𝑟𝑜𝑙
 (𝑡) − (𝑘03 + 𝑘05 + 𝑘𝑝19) 𝑉𝑐(𝑡)𝐶𝑐,pregnenolone 
 (𝑡) 
+𝑘𝑚19𝑉𝑚𝐶𝑚,pregnenolone
 (𝑡) 
𝑑[𝑉𝑚𝐶𝑚,𝑝𝑟𝑒𝑔𝑛𝑒𝑛𝑜𝑙𝑜𝑛𝑒(𝑡)]
𝑑𝑡
=  𝑘𝑝19𝑉𝑐(𝑡)𝐶𝑐,𝑝𝑟𝑒𝑔𝑛𝑒𝑛𝑜𝑙𝑜𝑛𝑒(𝑡) − 𝑘𝑚19𝑉𝑚(𝑡)𝐶𝑚,pregnenolone(𝑡) 
 
Progesterone: 
𝑑[𝑉𝑐(t)𝐶𝑐,progesterone
 (𝑡)]
𝑑𝑡
=  𝑘05𝑉𝑐(𝑡)𝐶𝑐,𝑝𝑟𝑒𝑔𝑛𝑒𝑛𝑜𝑙𝑜𝑛𝑒
 (𝑡) −  (𝑘08 + 𝑘11 + 𝑘𝑝20)𝑉𝑐(𝑡)𝐶𝑐,progesterone 
 (𝑡) 
+𝑘𝑚20𝑉𝑚𝐶𝑚,progesterone
 (𝑡) 
𝑑[𝑉𝑚𝐶𝑚,progesterone(𝑡)]
𝑑𝑡
=  𝑘𝑝20𝑉𝑐(𝑡)𝐶𝑐,progesterone(𝑡) − 𝑘𝑚20𝑉𝑚(𝑡)𝐶𝑚,progesterone(𝑡) 
 
Cortisol: 
𝑑[𝑉𝑐(t)𝐶𝑐,cortisol
 (𝑡)]
𝑑𝑡
=  𝑘17𝑉𝑐(𝑡)𝐶𝑐,11−deoxycortisol
 (𝑡) −  𝑘𝑝27𝑉𝑐(𝑡)𝐶𝑐,cortisol 
 (𝑡) 
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+𝑘𝑚27𝑉𝑚𝐶𝑚,cortisol
 (𝑡) 
𝑑[𝑉𝑚𝐶𝑚,cortisol(𝑡)]
𝑑𝑡
=  𝑘𝑝27𝑉𝑐(𝑡)𝐶𝑐,cortisol(𝑡) − 𝑘𝑚27𝑉𝑚(𝑡)𝐶𝑚,cortisol(𝑡) 
 
11-deoxycorticosterone: 
𝑑[𝑉𝑐(t)𝐶𝑐,11−deoxycorticosterone
 (𝑡)]
𝑑𝑡
=  𝑘11𝑉𝑐(𝑡)𝐶𝑐,progesterone
 (𝑡) − (𝑘16 + 𝑘𝑝21)𝑉𝑐(𝑡)𝐶𝑐,11−deoxycorticosterone 
 (𝑡) 
+𝑘𝑚21𝑉𝑚𝐶𝑚,11−deoxycorticosterone
 (𝑡) 
𝑑[𝑉𝑚𝐶𝑚,11−deoxycorticosterone(𝑡)]
𝑑𝑡
=  𝑘𝑝21𝑉𝑐(𝑡)𝐶𝑐,11−deoxycorticosterone(𝑡)
− 𝑘𝑚21𝑉𝑚(𝑡)𝐶𝑚,11−deoxycorticosterone(𝑡) 
 
Corticosterone: 
𝑑[𝑉𝑐(t)𝐶𝑐,corticosterone
 (𝑡)]
𝑑𝑡
=  𝑘16𝑉𝑐(𝑡)𝐶𝑐,11−deoxycorticosterone
 (𝑡) −  (𝑘18 + 𝑘𝑝22)𝑉𝑐(𝑡)𝐶𝑐,corticosterone 
 (𝑡) 
+𝑘𝑚22𝑉𝑚𝐶𝑚,corticosterone
 (𝑡) 
𝑑[𝑉𝑚𝐶𝑚,corticosterone(𝑡)]
𝑑𝑡
=  𝑘𝑝22𝑉𝑐(𝑡)𝐶𝑐,corticosterone(𝑡) − 𝑘𝑚22𝑉𝑚(𝑡)𝐶𝑚,corticosterone(𝑡) 
 
Aldosterone: 
𝑑[𝑉𝑐(t)𝐶𝑐,aldosterone
 (𝑡)]
𝑑𝑡
=  𝑘18𝑉𝑐(𝑡)𝐶𝑐,corticosterone
 (𝑡) − 𝑘𝑝23𝑉𝑐(𝑡)𝐶𝑐,aldosterone 
 (𝑡) 
+𝑘𝑚23𝑉𝑚𝐶𝑚,aldosterone
 (𝑡) 
𝑑[𝑉𝑚𝐶𝑚,aldosterone(𝑡)]
𝑑𝑡
=  𝑘𝑝23𝑉𝑐(𝑡)𝐶𝑐,aldosterone(𝑡) − 𝑘𝑚23𝑉𝑚(𝑡)𝐶𝑚,aldosterone(𝑡) 
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17Oh-progesterone: 
𝑑[𝑉𝑐(t)𝐶𝑐,17Oh−progesterone
 (𝑡)]
𝑑𝑡
=  𝑘08𝑉𝑐(𝑡)𝐶𝑐,progesterone
 (𝑡) 
+𝑘06𝑉𝑐(𝑡)𝐶𝑐,17𝑂𝐻−𝑝𝑟𝑒𝑔𝑛𝑒𝑛𝑜𝑙𝑜𝑛𝑒
 (𝑡) −  (𝑘09 + 𝑘12 + 𝑘𝑝25)𝑉𝑐(𝑡)𝐶𝑐,17Oh−progesterone 
 (𝑡)  
+𝑘𝑚25𝑉𝑚𝐶𝑚,17Oh−progesterone
 (𝑡) 
𝑑[𝑉𝑚𝐶𝑚,17Oh−progesterone(𝑡)]
𝑑𝑡
=  𝑘𝑝25𝑉𝑐(𝑡)𝐶𝑐,17Oh−progesterone(𝑡) − 𝑘𝑚25𝑉𝑚(𝑡)𝐶𝑚,17Oh−progesterone(𝑡) 
 
17Oh-pregnenolone: 
𝑑[𝑉𝑐(t)𝐶𝑐,17Oh−pregnenolone
 (𝑡)]
𝑑𝑡
=  𝑘03𝑉𝑐(𝑡)𝐶𝑐,pregnenolone
 (𝑡) 
− (𝑘04 + 𝑘06 + 𝑘𝑝24)𝑉𝑐(𝑡)𝐶𝑐,17Oh−pregnenolone 
 (𝑡)  
+𝑘𝑚25𝑉𝑚𝐶𝑚,17Oh−pregnenolone
 (𝑡) 
𝑑[𝑉𝑚𝐶𝑚,17Oh−pregnenolone(𝑡)]
𝑑𝑡
=  𝑘𝑝24𝑉𝑐(𝑡)𝐶𝑐,17Oh−pregnenolone(𝑡) − 𝑘𝑚24𝑉𝑚(𝑡)𝐶𝑚,17Oh−pregnenolone(𝑡) 
 
 
11-deoxycortisol: 
𝑑[𝑉𝑐(t)𝐶𝑐,11−deoxycortisol
 (𝑡)]
𝑑𝑡
=  𝑘12𝑉𝑐(𝑡)𝐶𝑐,17Oh−progesterone
 (𝑡) −  (𝑘17 + 𝑘𝑝26)𝑉𝑐(𝑡)𝐶𝑐,11−deoxycortisol 
 (𝑡) 
+𝑘𝑚26𝑉𝑚𝐶𝑚,11−deoxycortisol
 (𝑡) 
𝑑[𝑉𝑚𝐶𝑚,11−deoxycortisol(𝑡)]
𝑑𝑡
=  𝑘𝑝26𝑉𝑐(𝑡)𝐶𝑐,11−deoxycortisol(𝑡) − 𝑘𝑚26𝑉𝑚(𝑡)𝐶𝑚,11−deoxycortisol(𝑡) 
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Androstenedione: 
𝑑[𝑉𝑐(t)𝐶𝑐,androstenedione
 (𝑡)]
𝑑𝑡
=  𝑘07𝑉𝑐(𝑡)𝐶𝑐,𝐷𝐻𝐸𝐴
 (𝑡) + 𝑘09𝑉𝑐(𝑡)𝐶𝑐,17𝑂ℎ−𝑝𝑟𝑜𝑔𝑒𝑠𝑡𝑒𝑟𝑜𝑛𝑒
 (𝑡) 
+𝑘𝑚20𝑉𝑚𝐶𝑚,𝑎𝑛𝑑𝑟𝑜𝑠𝑡𝑒𝑛𝑒𝑑𝑖𝑜𝑛𝑒
 (𝑡) −  𝑘𝑝20𝑉𝑐(𝑡)𝐶𝑐,𝑎𝑛𝑑𝑟𝑜𝑠𝑡𝑒𝑛𝑒𝑑𝑖𝑜𝑛𝑒
 (𝑡) 
𝑑[𝑉𝑚𝐶𝑚,androstenedione(𝑡)]
𝑑𝑡
=  𝑘𝑝20𝑉𝑐(𝑡)𝐶𝑐,androstenedione(𝑡) − 𝑘𝑚20𝑉𝑚(𝑡)𝐶𝑚,androstenedione(𝑡) 
 
DHEA: 
𝑑[𝑉𝑐(t)𝐶𝑐,DHEA
 (𝑡)]
𝑑𝑡
=  𝑘04𝑉𝑐(𝑡)𝐶𝑐,17𝑂ℎ−𝑝𝑟𝑒𝑔𝑛𝑒𝑛𝑜𝑙𝑜𝑛𝑒
 (𝑡) −  𝑘07𝑉𝑐(𝑡)𝐶𝑐,DHEA 
 (𝑡) 
+𝑘𝑚17𝑉𝑚𝐶𝑚,DHEA
 (𝑡) −  𝑘𝑝17𝑉𝑐(𝑡)𝐶𝑐,DHEA
 (𝑡) 
𝑑[𝑉𝑚𝐶𝑚,DHEA(𝑡)]
𝑑𝑡
=  𝑘𝑝17𝑉𝑐(𝑡)𝐶𝑐,DHEA(𝑡) − 𝑘𝑚17𝑉𝑚(𝑡)𝐶𝑚,DHEA(𝑡) 
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A2. Jsim MML example code of the ODE system implementation of the 
static culture model  
import nsrunit; 
unit conversion on; 
math main{ 
 // time intervals definition 
realDomain t hr; 
 t.min =   0; 
 t.max = 48; 
 t.delta = 0.1;  
  
// initial experimental parameter setting  
 real scale = 2e5;    // Cell number 
 real VsingleCell = 659.8 um^3;  // Cell volume  
 real Vmedi = 600 mm^3;   // volume of medium in wells 
 real Vcell0 = scale*VsingleCell;  // total initial cell volume 
  
// definition of time-dependent variables 
real Vcell(t);  
real CmCHOL(t) nM;  real CcCHOL(t) nM; 
 real CmPREG(t) nM;  real CcPREG(t) nM; 
 real CmHPREG(t) nM; real CcHPREG(t) nM; 
 real CmDHEA(t) nM;  real CcDHEA(t) nM; 
 real CmPROG(t) nM;  real CcPROG(t) nM; 
 real CmHPROG(t) nM; real CcHPROG(t) nM; 
 real CmDIONE(t) nM;  real CcDIONE(t) nM; 
 real CmT(t) nM;  real CcT(t) nM; 
 real CmDCORTICO(t) nM; real CcDCORTICO(t) nM; 
 real CmCORTICO(t) nM; real CcCORTICO(t) nM; 
 real CmALDO(t) nM;  real CcALDO(t) nM; 
 real CmDCORT(t) nM; real CcDCORT(t) nM; 
 real CmCORT(t) nM;  real CcCORT(t) nM;  
 
// parameters of metabolic pathways – initial values based on Breen et al - 2011 
 real   k01 = 0.0138 1/hr ; 
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 real   k02 = 0.0836 1/hr ; 
 real   k03 = 2.386 1/hr ; 
 real   k04 = 1.129 1/hr ; 
 real   k05 = 1.058 1/hr ; 
 real   k06 = 13.289 1/hr ; 
 real   k07 = 10.538 1/hr ; 
 real   k08 = 1.267 1/hr ; 
 real   k09 = 0.4291 1/hr ; 
 real   k10 = 0.0048 1/hr ; 
 real   k11 = 3.37 1/hr ; 
 real   k12 = 8.714 1/hr ; 
 real   k16 = 1.171 1/hr ; 
 real   k17 = 1.027 1/hr ; 
 real   k18 = 0.0512 1/hr ; 
  
// equilibrium parameters (i.e. qi = kpi/kmi) 
 real   q19 = 0.0235  ; 
 real   q20 = 1.304  ; 
 real   q21 = 0.8979  ; 
 real   q22 = 0.0992  ; 
 real   q23 = 1.858  ; 
 real   q24 = 0.0955  ; 
 real   q25 = 3.402  ; 
 real   q26 = 2.481  ; 
 real   q27 = 0.002  ; 
 real   q28 = 1.102  ; 
 real   q29 = 0.5693  ; 
 real   q31 = 0.1157  ; 
// rate constant parameters 
 real   km19 = 0.1423 1/hr ; 
 real   km20 = 1.919 1/hr ; 
 real   km21 = 0.2385 1/hr ; 
 real   km22 = 1.121 1/hr ; 
 real   km23 = 5.04E-07 1/hr ; 
 real   km24 = 0.0967 1/hr ; 
76 
 
 real km25 = 0.2431 1/hr ; 
 real km26 = 0.0602 1/hr ; 
 real km27 = 1.012 1/hr ; 
 real km28 = 0.1213 1/hr ; 
 real km29 = 0.1677 1/hr ; 
 real km31 = 1.091 1/hr ; 
 real  kp19 = q19*km19 ; 
 real kp20 = q20*km20 ; 
 real kp21 = q21*km21 ; 
 real  kp22 = q22*km22 ; 
 real kp23 = q23*km23 ; 
 real kp24 = q24*km24 ; 
 real kp25 = q25*km25 ; 
 real kp26 = q26*km26 ; 
 real  kp27 = q27*km27 ; 
 real  kp28 = q28*km28 ; 
 real  kp29 = q29*km29 ; 
 real  kp30 = q30*km30 ; 
 real  kp31 = q31*km31 ; 
 real  kp32  = q32*km32 ; 
 
 // initial conditions for time-dependent variables – experimental data 
 when (t=t.min) 
 { 
  CcCHOL     = 2525000; CmCHOL = 20275; 
  CcPREG       = 1267;  CmPREG     = 0.08125; 
  CcHPREG    = 0.00e0;  CmHPREG    = 0; 
  CcDHEA     = 501;  CmDHEA     = 0.13; 
  CcPROG     = 4.27;  CmPROG     = 0.9; 
  CcHPROG    = 13.82;  CmHPROG    = 3.32; 
   CcT        = 0.00e0;  CmT        = 0.3; 
  CcDIONE    = 312.5;  CmDIONE      = 0.02; 
  CcDCORTICO = 112.206; CmDCORTICO = 1.6; 
  CcCORTICO  = 305.641; CmCORTICO  = 1.9; 
  CcALDO     = 0.00e0;  CmALDO     = 0.02; 
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  CcDCORT    = 10150; CmDCORT    = 7.528; 
  CcCORT     = 460;  CmCORT     = 0.7376; 
  Vcell      = Vcell0; 
} 
 
 real kp = 0.0273 1/hr;    // experimental value 
 Vcell = Vcell0 * exp(kp*(t)); 
 
 (Vcell*CcCHOL):t =  k01*Vmedi*CmCHOL-(k00+k02)*Vcell*CcCHOL; 
 (Vmedi*CmCHOL):t = -k01*Vmedi*CmCHOL; 
 
(Vcell*CcPREG):t = k02*Vcell*CcCHOL-
(k03+k05+kp19)*Vcell*CcPREG+km19*Vmedi*CmPREG; 
 (Vmedi*CmPREG):t = kp19*Vcell*CcPREG-km19*Vmedi*CmPREG; 
 
(Vcell*CcHPREG):t = k03*Vcell*CcPREG-
(k04+k06+kp24)*Vcell*CcHPREG+km24*Vmedi*CmHPREG; 
 (Vmedi*CmHPREG):t = kp24*Vcell*CcHPREG-km24*Vmedi*CmHPREG; 
 
(Vcell*CcDHEA):t = k04*Vcell*CcHPREG-
(k07+kp28)*Vcell*CcDHEA+km28*Vmedi*CmDHEA; 
 (Vmedi*CmDHEA):t = kp28*Vcell*CcDHEA-km28*Vmedi*CmDHEA; 
 
(Vcell*CcPROG):t = k05*Vcell*CcPREG-
(k08+k11+kp20)*Vcell*CcPROG+km20*Vmedi*CmPROG; 
 (Vmedi*CmPROG):t = kp20*Vcell*CcPROG-km20*Vmedi*CmPROG; 
 
(Vcell*CcHPROG):t = k06*Vcell*CcHPREG+k08*Vcell*CcPROG-
(k09+k12+kp25)*Vcell*CcHPROG+km25*Vmedi*CmHPROG; 
 (Vmedi*CmHPROG):t = kp25*Vcell*CcHPROG-km25*Vmedi*CmHPROG; 
 
(Vcell*CcDIONE):t = k07*Vcell*CcDHEA+k09*Vcell*CcHPROG-
(k10+k13+kp29)*Vcell*CcDIONE+km29*Vmedi*CmDIONE; 
 (Vmedi*CmDIONE):t = kp29*Vcell*CcDIONE-km29*Vmedi*CmDIONE; 
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 (Vcell*CcT):t = k10*Vcell*CcDIONE-(k14+kp31)*Vcell*CcT+km31*Vmedi*CmT; 
 (Vmedi*CmT):t = kp31*Vcell*CcT-km31*Vmedi*CmT; 
 
(Vcell*CcE1):t = k13*Vcell*CcDIONE-
(k15+kp30)*Vcell*CcE1+km30*Vmedi*CmE1; 
 (Vmedi*CmE1):t = kp30*Vcell*CcE1-km30*Vmedi*CmE1; 
 
(Vcell*CcE2):t = k14*Vcell*CcT+k15*Vcell*CcE1-
kp32*Vcell*CcE2+km32*Vmedi*CmE2; 
 (Vmedi*CmE2):t = kp32*Vcell*CcE2-km32*Vmedi*CmE2; 
 
(Vcell*CcDCORTICO):t = k11*Vcell*CcPROG-
(k16+kp21)*Vcell*CcDCORTICO+km21*Vmedi*CmDCORTICO; 
(Vmedi*CmDCORTICO):t = kp21*Vcell*CcDCORTICO-
km21*Vmedi*CmDCORTICO; 
 
(Vcell*CcCORTICO):t = k16*Vcell*CcDCORTICO-
(k18+kp22)*Vcell*CcCORTICO+km22*Vmedi*CmCORTICO; 
(Vmedi*CmCORTICO):t = kp22*Vcell*CcCORTICO-
km22*Vmedi*CmCORTICO; 
 
(Vcell*CcALDO):t = k18*Vcell*CcCORTICO-
kp23*Vcell*CcALDO+km23*Vmedi*CmALDO; 
 (Vmedi*CmALDO):t = kp23*Vcell*CcALDO-km23*Vmedi*CmALDO; 
 
(Vcell*CcDCORT):t = k12*Vcell*CcHPROG-
(k17+kp26)*Vcell*CcDCORT+km26*Vmedi*CmDCORT; 
 (Vmedi*CmDCORT):t = kp26*Vcell*CcDCORT-km26*Vmedi*CmDCORT; 
 
(Vcell*CcCORT):t = k17*Vcell*CcDCORT-
kp27*Vcell*CcCORT+km27*Vmedi*CmCORT; 
 (Vmedi*CmCORT):t = kp27*Vcell*CcCORT-km27*Vmedi*CmCORT; 
}  
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A3. Supplementary data for static culture model derived data 
 
A3, Table 1: Quantitative ranges for the first experimental set-up: Stimulation 
with angII and forskolin 
 
 Quantitative ranges of medium concentrations 
(nM) 
Steroid Untreated cells Angiotensin II Forskolin 
Aldosterone 0.024-0.263 0.006-0.658 0.017-0.459 
Androstenedione 0.944-94.031 1.203-111.336 2.048-480.287 
Corticosterone 0.275-8.012 0.199-21.099 0.780-77.885 
Cortisol 0.913-10.742 1.115-19.564 1.193-138.905 
11-deoxycorticosterone 2.029-86.122 3.164-95.881 4.469-96.272 
11-deoxycortisol 3.624-252.204 5.395-246.974 6.255-391.363 
DHEA 0.129-1.017 0.103-0.898 3.451-5.280 
17OH-progesterone 1.150-30.669 1.426-32.752 9.987-64.793 
Progesterone 7.596-31.487 4.056-51.122 12.269-88.948 
Pregnenolone 1.581-9.057 1.272-15.998 2.480-29.354 
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A3, Table 2: Quantitative ranges for the second experimental set-up: Inhibition 
with abiraterone 
 
 Quantitative ranges of medium 
concentrations (nM) 
Steroid Untreated cells Abiraterone 
Aldosterone 0.205-0.359 0.121-0.382 
Androstenedione 0.957-165.614 0.743-36.661 
Corticosterone 0.337-6.126 0.220-11.786 
Cortisol 1.001-4.684 0.480-1.773 
11-deoxycorticosterone 1.490-93.808 0.843-114.764 
11-deoxycortisol 1.255-184.148 0.755-90.469 
DHEA 0.180-1.165 0.000-0.386 
17OH-progesterone 0.846-41.205 0.545-16.679 
Progesterone 7.343-62.128 3.604-73.152 
Pregnenolone 2.581-21.128 0.661-16.073 
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A3, Table 3: Secretion and import rates of transport pathways for stimulation 
with angII and forskolin are presented as ratios, 𝑟𝑥 =  
𝑘+,𝑥
𝑘−,𝑥
. 
 Control Angiotensin II Forskolin 
r15 0.209 0.259 0.172 
r16 0.096 0.009 0.612 
r17 0.695 0.712 2.500 
r18 2.314 2.453 2.489 
r19 4.03 3.955 3.877 
r20 0.539 0.388 2.037 
r21 1.247 1.545 1.191 
r22 3.439 3.500 3.171 
r23 0.039 0.215 0.777 
r24 0.003 0.004 0.043 
r25 1.858 2.058 1.858 
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A3, Table 4: Rates for transport pathways and inhibition with abiraterone. 
Secretion and import rates are presented as ratios, 𝑟𝑥 =  
𝑘+,𝑥
𝑘−,𝑥
 , and abiraterone 
inhibition constants in nM.   
 
 
 Control Abiraterone Units 
r15 0.320 0.272 - 
r16 0.096 0.097 - 
r17 0.696 0.0004 - 
r18 2.696 2.698 - 
r19 4.033 4.035 - 
r20 0.506 0.508 - 
r21 1.207 1.226 - 
r22 3.346 3.368 - 
r23 0.019 0.034 - 
r24 0.001 0.0005 - 
r25 1.858 1.858 - 
r33 - 0.006 - 
KI3 - 13.265 nM 
KI4 - 40.571 nM 
KI8 - 23.2 nM 
KI9 - 10.022 nM 
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A3, Figure 1: A. Number of viable cells in all conditions. B. Cell viability in all conditions. 
 
  
A3, Figure 2: A. Medium concentrations of DHEA in untreated cells (control) (●), with 
angII (▪) and forskolin ( ) stimulation. Data points for all seven time points of 0, 2, 6, 10, 
24, 34 and 48 hours are presented as mean concentrations in nM ± SE. Model generated 
curves are plotted for each condition, control (straight blue line), angiotensin (dashed 
green line) and forskolin (dots and dashes red line). B. Medium concentrations of DHEA 
measured at seven times points (0, 2, 6, 10, 24, 34 and 48 hours) in untreated cells 
(control) (●) and with abiraterone inhibition (▪), presented as mean concentrations in nM 
± SE. Model generated curves are plotted as functions of time for each condition, control 
(straight line) and abiraterone inhibition (dashed line). 
  
 
A. B. 
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Appendix B – Steady state model 
B1. Mathematical derivation of analytical solution for intracellular flux 
calculation of the steady state model 
The mathematical models used in this study are solely based on mass balance and 
mass reaction equations, which are reduced accordingly to describe a steady state 
system. Let us assume a system consisting of two compartments, the cells (with a total 
volume  𝑉𝑐) and a chamber of volume  𝑉𝑚 , filled with flowing medium of flow F 
(supplementary material, appendix B1, figure1).  
 
Supplementary material, appendix B1, figure 1: Mathematical modeling approximation 
of metabolic processes in the steady state system. In the cell interior, cells are 
converted from precursors to products under intracellular flux rates (in mol/min) and 
then secreted in the flowing medium under the secretion rates (in mol/min). The LC-MS 
calculated concentrations allow for calculation of the secretion rates and subsequently 
of the intracellular flux rates.   
 
Steroid x is produced in the cells by a precursor through an enzymatic reaction with a 
rate constant 𝑘𝑝𝑟𝑒 under a flux rate 𝑣𝑝𝑟𝑒 , and converted further by an enzymatic 
reaction with a rate constant 𝑘𝑝𝑟𝑜 under a flux rate 𝑣𝑝𝑟𝑜. Concentration of steroid x in 
the cells is notated as [ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥𝑐𝑒𝑙𝑙] and in the medium as [ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥𝑚𝑒𝑑]. Steroid x is 
secreted under a secretion rate 𝐽𝑥 which is defined by the transport constants 𝑘+ and 
 𝑘−, representing the secretion and uptake of steroid x by the cell, respectively. In 
addition steroid x is flowing into the chamber at a concentration [𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥𝑖𝑛].  The 
equation that describes the rate of change of the steroid x concentration in the medium 
is: 
𝑉𝑚
𝑑[ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑚𝑒𝑑(t)]
𝑑𝑡
= 𝐹 ∙ [𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑖𝑛] − F ∙ [ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑚𝑒𝑑(𝑡)] 
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+𝑘+ ∙ 𝑉𝑐 ∙ [ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑐𝑒𝑙𝑙(t) ] − 𝑘− ∙ [ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑚𝑒𝑑(𝑡)] ∙ 𝑉𝑚 (1) 
Due to the fact that the flowing medium at the input does not contain calculable steroid 
concentrations we can assume that [𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥𝑖𝑛] = 0. Also, due to the flowing medium 
steroids are unlikely to be able to be reabsorbed by the cells, therefore we can assume 
that  𝑘− ≅ 0. In addition, due to our steady state approximation, 
𝑑[ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑚𝑒𝑑(t)]
𝑑𝑡
= 0. 
Based on these assumptions equation (1) transforms to:  
0 = −F ∙ [ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑚𝑒𝑑] + 𝑘+ ∙ 𝑉𝑐 ∙ [ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑐𝑒𝑙𝑙 ]  
⇔  𝐽𝑥 = F ∙ [ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑚𝑒𝑑] = 𝑘+ ∙ 𝑉𝑐 ∙ [ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑐𝑒𝑙𝑙 ]        (2) 
The rate of change of the intracellular steroid x concentration is given by the following 
equation: 
𝑉𝑐
𝑑[ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑐𝑒𝑙𝑙]
𝑑𝑡
= 𝑘𝑝𝑟𝑒[𝑝𝑟𝑒𝑐𝑢𝑟𝑠𝑜𝑟(𝑡)] ∙ 𝑉𝑐 − 𝑘𝑝𝑟𝑜 ∙ [ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑐𝑒𝑙𝑙(𝑡)] ∙ 𝑉𝑐 
                                      −𝑘+ ∙ 𝑉𝑐 ∙ [ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑐𝑒𝑙𝑙(t) ] + 𝑘− ∙ [ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑚𝑒𝑑(𝑡)] ∙ 𝑉𝑚 (3) 
Based on the assumptions mentioned above, 𝑑[ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑐𝑒𝑙𝑙(t)]
𝑑𝑡
= 0 and   𝑘− = 0, equation 
(3) transforms to: 
0 = 𝑘𝑝𝑟𝑒[𝑝𝑟𝑒𝑐𝑢𝑟𝑠𝑜𝑟] ∙ 𝑉𝑐 − 𝑘𝑝𝑟𝑜 ∙ [ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑐𝑒𝑙𝑙] ∙ 𝑉𝑐 − 𝑘+ ∙ 𝑉𝑐 ∙ [ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑐𝑒𝑙𝑙] 
⇔ 𝑘𝑝𝑟𝑒[𝑝𝑟𝑒𝑐𝑢𝑟𝑠𝑜𝑟] ∙ 𝑉𝑐 = 𝑘𝑝𝑟𝑜[ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑐𝑒𝑙𝑙] ∙ 𝑉𝑐 + 𝑘+[ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑐𝑒𝑙𝑙  ]  ∙ 𝑉𝑐        (4) 
Based on eq. (4) and using eq. (2) we can derive the flux balance equation which is 
used in our system: 
⇔  𝑣𝑝𝑟𝑒 = 𝑣𝑝𝑟𝑜 + 𝐽𝑥         (5) 
The full system of equations describing steroid production which is derived from the 
above methodology is presented in appendix B2.  
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B2. Equations describing steroid production in cells and flowing medium 
of the steady state model  
The mathematical formulation of steroidogenesis as derived from the mass balance 
equation is presented in this section analytically. The steroidogenic pathways are 
modelled according to figure 2 of the appendix.  
 
 
Supplementary material, appendix 1b, figure 2: Schematic representation of the steroid 
production pathways. Steroids are produced in the cell interior and then secreted to the 
cell exterior through the cell membrane, process that is described by the transport 
constants m. All steroidogenic reactions are described by the rate constant k and the flux 
rate v. Cholesterol transport to the cell interior and subsequent conversion to 
pregnenolone is approximated as one process and represented by the flux rate v01.  
Pregnenolone: 
 
𝑑[𝑉𝑐𝐶𝑐,pregnenolone
 (𝑡)]
𝑑𝑡
=  𝑘01𝑉𝑐𝐶𝑚,cholesterol(𝑡) −  (𝑚11 + 𝑘31 + 𝑘11 + 𝑘21) 𝑉𝑐𝐶𝑐,pregnenolone 
 (𝑡) 
𝑑[𝑉𝑚𝐶𝑚,𝑝𝑟𝑒𝑔𝑛𝑒𝑛𝑜𝑙𝑜𝑛𝑒(𝑡)]
𝑑𝑡
=  𝑚11𝑉𝑐𝐶𝑐,𝑝𝑟𝑒𝑔𝑛𝑒𝑛𝑜𝑙𝑜𝑛𝑒(𝑡) − 𝐹𝐶𝑚,pregnenolone(𝑡) 
𝑈𝑛𝑑𝑒𝑟 𝑠𝑡𝑒𝑎𝑑𝑦 𝑠𝑡𝑎𝑡𝑒,
𝑑[𝑉𝑐𝐶𝑐,pregnenolone
 ]
𝑑𝑡
=  0 𝑎𝑛𝑑 
𝑑[𝑉𝑚𝐶𝑚,𝑝𝑟𝑒𝑔𝑛𝑒𝑛𝑜𝑙𝑜𝑛𝑒]
𝑑𝑡
=  0 
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  ⇒ 𝐹𝐶𝑚,pregnenolone =  𝑚11𝑉𝑐𝐶𝑐,𝑝𝑟𝑒𝑔𝑛𝑒𝑛𝑜𝑙𝑜𝑛𝑒     (M1) 
⇒ (𝑘31 + 𝑘11 + 𝑘21) 𝑉𝑐𝐶𝑐,pregnenolone 
 =  𝑘01𝐶𝑚,cholesterol −  
𝐹
𝑉𝑐
𝐶𝑚,pregnenolone    (C1) 
Progesterone: 
𝑑[𝑉𝑐𝐶𝑐,progesterone
 (𝑡)]
𝑑𝑡
=  𝑘11𝑉𝑐𝐶𝑐,𝑝𝑟𝑒𝑔𝑛𝑒𝑛𝑜𝑙𝑜𝑛𝑒
 (𝑡) −  (𝑚12 + 𝑘12 + 𝑘𝑣𝑣1)𝑉𝑐𝐶𝑐,progesterone 
 (𝑡) 
𝑑[𝑉𝑚𝐶𝑚,progesterone(𝑡)]
𝑑𝑡
=  𝑚12𝑉𝑐𝐶𝑐,progesterone(𝑡) − 𝐹𝐶𝑚,progesterone(𝑡) 
𝑈𝑛𝑑𝑒𝑟 𝑠𝑡𝑒𝑎𝑑𝑦 𝑠𝑡𝑎𝑡𝑒,
𝑑[𝑉𝑐𝐶𝑐,progesterone
 ]
𝑑𝑡
=  0 𝑎𝑛𝑑 
𝑑[𝑉𝑚𝐶𝑚,progesterone]
𝑑𝑡
=  0 
⇒ 𝑚12𝑉𝑐𝐶𝑐,progesterone =  𝐹𝐶𝑚,progesterone    (M2) 
⇒ 𝑘11𝐶𝑐,𝑝𝑟𝑒𝑔𝑛𝑒𝑛𝑜𝑙𝑜𝑛𝑒
 − (𝑘12 + 𝑘𝑣𝑣1)𝐶𝑐,progesterone 
 =  
𝐹
𝑉𝑐
𝐶𝑚,progesterone   (C2) 
11-deoxycorticosterone: 
𝑑[𝑉𝑐𝐶𝑐,11−deoxycorticosterone
 (𝑡)]
𝑑𝑡
=  𝑘12𝑉𝑐𝐶𝑐,progesterone
 (𝑡) − (𝑘13 + 𝑚13)𝑉𝑐𝐶𝑐,11−deoxycorticosterone 
 (𝑡) 
𝑑[𝑉𝑚𝐶𝑚,11−deoxycorticosterone(𝑡)]
𝑑𝑡
=  𝑚13𝑉𝑐𝐶𝑐,11−deoxycorticosterone(𝑡) − 𝐹𝐶𝑚,11−deoxycorticosterone(𝑡) 
𝑈𝑛𝑑𝑒𝑟 𝑠𝑡𝑒𝑎𝑑𝑦 𝑠𝑡𝑎𝑡𝑒,
𝑑[𝑉𝑐𝐶𝑐,11−deoxycorticosterone
 ]
𝑑𝑡
=  0 𝑎𝑛𝑑 
𝑑[𝑉𝑚𝐶𝑚,11−deoxycorticosterone]
𝑑𝑡
=  0 
⇒ 𝑚13𝑉𝑐𝐶𝑐,11−deoxycorticosterone =  𝐹𝐶𝑚,11−deoxycorticosterone    (M3) 
⇒ 𝑘12𝐶𝑐,progesterone
 − 𝑘13𝐶𝑐,11−deoxycorticosterone 
 =  
𝐹
𝑉𝑐
𝐶𝑚,11−deoxycorticosterone     (C3) 
Corticosterone: 
𝑑[𝑉𝑐𝐶𝑐,corticosterone
 (𝑡)]
𝑑𝑡
=  𝑘13𝑉𝑐𝐶𝑐,11−deoxycorticosterone
 (𝑡) − (𝑘14 + 𝑚14)𝑉𝑐𝐶𝑐,corticosterone 
 (𝑡) 
𝑑[𝑉𝑚𝐶𝑚,corticosterone(𝑡)]
𝑑𝑡
=  𝑚14𝑉𝑐𝐶𝑐,corticosterone(𝑡) − 𝐹𝐶𝑚,corticosterone(𝑡) 
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𝑈𝑛𝑑𝑒𝑟 𝑠𝑡𝑒𝑎𝑑𝑦 𝑠𝑡𝑎𝑡𝑒,
𝑑[𝑉𝑐𝐶𝑐,corticosterone
 ]
𝑑𝑡
=  0 𝑎𝑛𝑑 
𝑑[𝑉𝑚𝐶𝑚,corticosterone]
𝑑𝑡
=  0 
⇒ 𝑚14𝑉𝑐𝐶𝑐,corticosterone =  𝐹𝐶𝑚,corticosterone    (M4) 
⇒  𝑘13𝐶𝑐,11−deoxycorticosterone
 −  𝑘14𝐶𝑐,corticosterone 
 =
𝐹
𝑉𝑐
𝐶𝑚,corticosterone    (C4) 
Aldosterone: 
𝑑[𝑉𝑐𝐶𝑐,aldosterone
 (𝑡)]
𝑑𝑡
=  𝑚14𝑉𝑐𝐶𝑐,corticosterone
 (𝑡) − 𝑘15𝑉𝑐𝐶𝑐,aldosterone 
 (𝑡) 
𝑑[𝑉𝑚𝐶𝑚,aldosterone(𝑡)]
𝑑𝑡
=  𝑘15𝑉𝑐𝐶𝑐,aldosterone(𝑡) − 𝐹𝐶𝑚,aldosterone(𝑡) 
𝑈𝑛𝑑𝑒𝑟 𝑠𝑡𝑒𝑎𝑑𝑦 𝑠𝑡𝑎𝑡𝑒,
𝑑[𝑉𝑐𝐶𝑐,aldosterone
 ]
𝑑𝑡
=  0 𝑎𝑛𝑑 
𝑑[𝑉𝑚𝐶𝑚,aldosterone]
𝑑𝑡
=  0 
⇒ 𝑚15𝑉𝑐𝐶𝑐,aldosterone =  𝐹𝐶𝑚,aldosterone    (M5) 
⇒ 𝑘14𝐶𝑐,corticosterone
 =  
𝐹
𝑉𝑐
𝐶𝑚,aldosterone    (C5) 
17Oh-progesterone: 
𝑑[𝑉𝑐𝐶𝑐,17Oh−progesterone
 (𝑡)]
𝑑𝑡
=  𝑘𝑣𝑣1𝑉𝑐𝐶𝑐,progesterone
 (𝑡) + 𝑘21𝑉𝑐𝐶𝑐,𝑝𝑟𝑒𝑔𝑛𝑒𝑛𝑜𝑙𝑜𝑛𝑒
 (𝑡) − (𝑚21 +
𝑘12 + 𝑘𝑣𝑣2)𝑉𝑐𝐶𝑐,17Oh−progesterone 
 (𝑡)  
𝑑[𝑉𝑚𝐶𝑚,17Oh−progesterone(𝑡)]
𝑑𝑡
=  𝑚21𝑉𝑐𝐶𝑐,17Oh−progesterone(𝑡) − 𝐹𝐶𝑚,17Oh−progesterone(𝑡) 
𝑈𝑛𝑑𝑒𝑟 𝑠𝑡𝑒𝑎𝑑𝑦 𝑠𝑡𝑎𝑡𝑒,
𝑑[𝑉𝑐𝐶𝑐,17Oh−progesterone
 ]
𝑑𝑡
=  0 𝑎𝑛𝑑 
𝑑[𝑉𝑚𝐶𝑚,17Oh−progesterone]
𝑑𝑡
=  0  
⇒ 𝑚21𝑉𝑐𝐶𝑐,17Oh−progesterone =  𝐹𝐶𝑚,17Oh−progesterone    (M6) 
⇒  𝑘𝑣𝑣1𝐶𝑐,progesterone
 + 𝑘21𝐶𝑐,𝑝𝑟𝑒𝑔𝑛𝑒𝑛𝑜𝑙𝑜𝑛𝑒
 − (𝑘12 + 𝑘𝑣𝑣2)𝐶𝑐,17Oh−progesterone
 
=
𝐹
𝑉𝑐
𝐶𝑚,17Oh−progesterone    (C6) 
11-deoxycortisol: 
𝑑[𝑉𝑐𝐶𝑐,11−deoxycortisol
 (𝑡)]
𝑑𝑡
=  𝑘12𝑉𝑐𝐶𝑐,17Oh−progesterone
 (𝑡) −  (𝑚22 + 𝑘23)𝑉𝑐𝐶𝑐,11−deoxycortisol 
 (𝑡) 
𝑑[𝑉𝑚𝐶𝑚,11−deoxycortisol(𝑡)]
𝑑𝑡
=  𝑚22𝑉𝑐𝐶𝑐,11−deoxycortisol(𝑡) − 𝐹𝐶𝑚,11−deoxycortisol(𝑡) 
89 
 
𝑈𝑛𝑑𝑒𝑟 𝑠𝑡𝑒𝑎𝑑𝑦 𝑠𝑡𝑎𝑡𝑒,
𝑑[𝑉𝑐𝐶𝑐,11−deoxycortisol
 ]
𝑑𝑡
=  0 𝑎𝑛𝑑 
𝑑[𝑉𝑚𝐶𝑚,11−deoxycortisol]
𝑑𝑡
=  0 
⇒ 𝑚22𝑉𝑐𝐶𝑐,11−deoxycortisol =  𝐹𝐶𝑚,11−deoxycortisol    (M7) 
⇒ 𝑘12𝐶𝑐,17Oh−progesterone
 =  𝑘23𝐶𝑐,11−deoxycortisol
 +
𝐹
𝑉𝑐
𝐶𝑚,11−deoxycortisol    (C7) 
Cortisol: 
𝑑[𝑉𝑐𝐶𝑐,cortisol
 (𝑡)]
𝑑𝑡
=  𝑘23𝑉𝑐𝐶𝑐,11−deoxycortisol
 (𝑡) −  𝑚23𝑉𝑐𝐶𝑐,cortisol 
 (𝑡) 
𝑑[𝑉𝑚𝐶𝑚,cortisol(𝑡)]
𝑑𝑡
=  𝑚23𝑉𝑐𝐶𝑐,cortisol(𝑡) − 𝐹𝐶𝑚,cortisol(𝑡) 
𝑈𝑛𝑑𝑒𝑟 𝑠𝑡𝑒𝑎𝑑𝑦 𝑠𝑡𝑎𝑡𝑒,
𝑑[𝑉𝑐𝐶𝑐,cortisol
 ]
𝑑𝑡
=  0 𝑎𝑛𝑑 
𝑑[𝑉𝑚𝐶𝑚,cortisol]
𝑑𝑡
=  0 
⇒ 𝑚23𝑉𝑐𝐶𝑐,cortisol =  𝐹𝐶𝑚,cortisol    (M8) 
⇒  𝑘23𝐶𝑐,11−deoxycortisol
 =
𝐹
𝑉𝑐
𝐶𝑚,cortisol    (C8) 
DHEA: 
𝑑[𝑉𝑐𝐶𝑐,DHEA
 (𝑡)]
𝑑𝑡
=  𝑘31𝑉𝑐𝐶𝑐,𝑝𝑟𝑒𝑔𝑛𝑒𝑛𝑜𝑙𝑜𝑛𝑒
 (𝑡) − (𝑘32 + 𝑚32)𝑉𝑐𝐶𝑐,DHEA 
 (𝑡) 
𝑑[𝑉𝑚𝐶𝑚,DHEA(𝑡)]
𝑑𝑡
=  𝑚32𝑉𝑐𝐶𝑐,DHEA(𝑡) − 𝐹𝐶𝑚,DHEA(𝑡) 
𝑈𝑛𝑑𝑒𝑟 𝑠𝑡𝑒𝑎𝑑𝑦 𝑠𝑡𝑎𝑡𝑒,
𝑑[𝑉𝑐𝐶𝑐,DHEA
 ]
𝑑𝑡
=  0 𝑎𝑛𝑑 
𝑑[𝑉𝑚𝐶𝑚,DHEA]
𝑑𝑡
=  0 
⇒ 𝑚32𝑉𝑐𝐶𝑐,DHEA = 𝐹𝐶𝑚,DHEA    (M9) 
⇒  𝑘31𝐶𝑐,𝑝𝑟𝑒𝑔𝑛𝑒𝑛𝑜𝑙𝑜𝑛𝑒
 − 𝑘32𝐶𝑐,DHEA 
 =
𝐹
𝑉𝑐
𝐶𝑚,DHEA    (C9) 
Androstenedione: 
𝑑[𝑉𝑐𝐶𝑐,androstenedione
 (𝑡)]
𝑑𝑡
= 𝑘32𝑉𝑐𝐶𝑐,𝐷𝐻𝐸𝐴
 (𝑡) + 𝑘𝑣𝑣2𝑉𝑐𝐶𝑐,17𝑂ℎ−𝑝𝑟𝑜𝑔𝑒𝑠𝑡𝑒𝑟𝑜𝑛𝑒
 (𝑡) − (𝑘33
+ 𝑚33)𝑉𝑐𝐶𝑐,androstenedione 
 (𝑡) 
𝑑[𝑉𝑚𝐶𝑚,androstenedione(𝑡)]
𝑑𝑡
=  𝑚33𝑉𝑐𝐶𝑐,androstenedione(𝑡) − 𝐹𝐶𝑚,androstenedione(𝑡) 
90 
 
𝑈𝑛𝑑𝑒𝑟 𝑠𝑡𝑒𝑎𝑑𝑦 𝑠𝑡𝑎𝑡𝑒,
𝑑[𝑉𝑐𝐶𝑐,androstenedione
 ]
𝑑𝑡
= 0 𝑎𝑛𝑑 
𝑑[𝑉𝑚𝐶𝑚,androstenedione]
𝑑𝑡
=  0 
⇒ 𝑚33𝑉𝑐𝐶𝑐,androstenedione =  𝐹𝐶𝑚,androstenedione    (M10) 
⇒ 𝑘32𝐶𝑐,𝐷𝐻𝐸𝐴
 + 𝑘𝑣𝑣2𝐶𝑐,17𝑂ℎ−𝑝𝑟𝑜𝑔𝑒𝑠𝑡𝑒𝑟𝑜𝑛𝑒
 − 𝑘33𝐶𝑐,androstenedione 
 
=
𝐹
𝑉𝑐
𝐶𝑚,androstenedione    (C10) 
Testosterone: 
𝑑[𝑉𝑐𝐶𝑐,testosterone
 (𝑡)]
𝑑𝑡
=  𝑘33𝑉𝑐𝐶𝑐,𝑎𝑛𝑑𝑟𝑜𝑠𝑡𝑒𝑛𝑒𝑑𝑖𝑜𝑛𝑒
 (𝑡) − 𝑚34𝑉𝑐𝐶𝑐,testosterone 
 (𝑡) 
𝑑[𝑉𝑚𝐶𝑚,testosterone(𝑡)]
𝑑𝑡
=  𝑚34𝑉𝑐𝐶𝑐,testosterone(𝑡) − 𝐹𝐶𝑚,testosterone(𝑡) 
𝑈𝑛𝑑𝑒𝑟 𝑠𝑡𝑒𝑎𝑑𝑦 𝑠𝑡𝑎𝑡𝑒,
𝑑[𝑉𝑐𝐶𝑐,testosterone
 ]
𝑑𝑡
=  0 𝑎𝑛𝑑 
𝑑[𝑉𝑚𝐶𝑚,testosterone]
𝑑𝑡
=  0 
⇒ 𝑚34𝑉𝑐𝐶𝑐,testosterone = 𝐹𝐶𝑚,testosterone    (M11) 
⇒ 𝑘33𝐶𝑐,𝑎𝑛𝑑𝑟𝑜𝑠𝑡𝑒𝑛𝑒𝑑𝑖𝑜𝑛𝑒
 =
𝐹
𝑉𝑐
𝐶𝑚,testosterone    (C11) 
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B3. Quadratic programming formulation and solution of upstream 
steroidogenic pathways system of the steady state model 
Upstream steroidogenesis involves more complex pathways, forming an 
underdetermined mathematical system which contains more variables than equations. 
Such systems usually have a set of possible solutions, but the best fitting solution can 
be found by minimizing the norm of the system. This solution, also represents the more 
realistic one amongst all possibilities. The description of our system is described by eq. 
(4) of the thesis: 
𝐴 ∙ 𝑣 = 𝑦 
Subject to constrains that all flux components are positive  𝑣 ≥ 0.   
Or,  
 
In order to find the optimal solution, we applied the CVXOPT algorithm (M. S. Andersen, 
2012) (version 1.2.2,  2018) in PYTHON 2.7 under the Spyder 3.2.3 programming 
environment. CVXOPT is a python software package for convex optimization which 
requires a positive semidefinite quadratic programming formulation of our equation (4) 
as shown here: 
𝑚𝑖𝑛𝑥  
1
2
𝑥𝑇𝑃𝑥 + 𝑞𝑇𝑥        , 𝐺𝑥 ≥ ℎ  
The necessary formulations for the Euclidean norm, which gives the simplest solution to 
the problem (p=2), are analytically described below: 
𝑚𝑖𝑛 ‖𝐴𝑣 − 𝑦‖2,     𝑣 ≥ 0 
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‖𝐴𝑣 − 𝑦‖2 = 𝑣
𝑇𝐴𝑇𝐴𝑣 − 2𝑦𝑇𝐴𝑣 + 𝑐𝑜𝑛𝑠𝑡.  
=
1
2
𝑣𝑇(2𝐴𝑇𝐴)𝑣 + (−2𝑦𝑇𝐴)𝑣 + 𝑐𝑜𝑛𝑠𝑡. 
=
1
2
𝑣𝑇𝑃𝑣 + (𝑞𝑇)𝑣 
𝑤ℎ𝑒𝑟𝑒 𝑃 = 2𝐴𝑇𝐴 𝑎𝑛𝑑 𝑞𝑇 = −2𝑦𝑇𝐴  
The constant of the minimization can be ignored, since it has no effect on the result. 
Following derivation of matrices P and q, we applied the CVXOPT algorithm to the data 
(i.e. the calculated secretion rates, based on measured concentrations). CXVOPT 
algorithm in turn returns a matrix v containing the optimal solution for our under-
determined systems. Matrix v contains the optimal combination of all intracellular fluxes 
in our system which solves the above problem under our constrain.  This procedure was 
repeated for all experimental set-ups and mean values and standard deviations were 
derived and are presented in the manuscript.  
 
B4. Calculation of reaction rate constant relative changes 
If we consider eq. (2) of appendix 1 for control and inhibition and then divide the two 
equations, we derive: 
F ∙ [ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑚𝑒𝑑,𝑖𝑛ℎ]
F ∙ [ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑚𝑒𝑑,𝑐𝑛𝑡]
=
𝑘+
𝑖𝑛ℎ ∙ 𝑉𝑐 ∙ [ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑐𝑒𝑙𝑙,𝑖𝑛ℎ ]
𝑘+
𝑐𝑛𝑡 ∙ 𝑉𝑐 ∙ [ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑐𝑒𝑙𝑙,𝑐𝑛𝑡 ]
        (6) 
Since steroids are secreted either by diffusion or by mechanisms like this of p-
glycoprotein, we can safely assume that the transport constant will not differ for control 
and inhibition and thus  𝑘+𝑖𝑛ℎ =  𝑘+𝑐𝑛𝑡. Under this assumption eq. (6) is transformed to 
equation (7): 
[ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑚𝑒𝑑,𝑖𝑛ℎ]
[ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑚𝑒𝑑,𝑐𝑛𝑡]
=
[ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑐𝑒𝑙𝑙,𝑖𝑛ℎ ]
[ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑐𝑒𝑙𝑙,𝑐𝑛𝑡 ]
        (8) 
Furthermore, the equation describing the flux rate of a precursor steroid to the product 
is: 
𝑣𝑥 =  𝑘𝑥 ∙ [𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑝𝑟𝑒𝑐
𝑐𝑒𝑙𝑙  ] (9) 
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Where, 𝑣𝑥  is the flux rate of the conversion, 𝑘𝑥 is the rate constant and [𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑝𝑟𝑒𝑐𝑐𝑒𝑙𝑙  ] is 
the concentration of the precursor. If we consider eq. (9) for control and inhibition and 
then divide the two equations, we derive: 
𝑣𝑥
𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛
𝑣𝑥
𝑐𝑜𝑛𝑡𝑟𝑜𝑙 =
𝑘𝑥
𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛
𝑘𝑥
𝑐𝑜𝑛𝑡𝑟𝑜𝑙
𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑝𝑟𝑒𝑐
𝑐𝑒𝑙𝑙,𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛
𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑝𝑟𝑒𝑐
𝑐𝑒𝑙𝑙,𝑐𝑜𝑛𝑡𝑟𝑜𝑙  
⇒
𝑘𝑥
𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛
𝑘𝑥
𝑐𝑜𝑛𝑡𝑟𝑜𝑙
=
𝑣𝑥𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛
𝑣𝑥
𝑐𝑜𝑛𝑡𝑟𝑜𝑙
 
𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑝𝑟𝑒𝑐
𝑐𝑒𝑙𝑙,𝑐𝑜𝑛𝑡𝑟𝑜𝑙
𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑝𝑟𝑒𝑐
𝑐𝑒𝑙𝑙,𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛
          (10) 
Given eq. (8) we get the final formulas for estimating rate constant relative changes: 
⇒
𝑘𝑥
𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛
𝑘𝑥
𝑐𝑜𝑛𝑡𝑟𝑜𝑙
=
𝑣𝑥𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛
𝑣𝑥
𝑐𝑜𝑛𝑡𝑟𝑜𝑙
 
[ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑚𝑒𝑑,𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛
]
[ 𝑠𝑡𝑒𝑟𝑜𝑖𝑑𝑥
𝑚𝑒𝑑,𝑐𝑜𝑛𝑡𝑟𝑜𝑙
]
          (11) 
And  
𝐷𝑘𝑥 =
(𝑘𝑥
𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 − 𝑘𝑥
𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
𝑘𝑥
𝑐𝑜𝑛𝑡𝑟𝑜𝑙 ∙ 100 = (
𝑘𝑥
𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛
𝑘𝑥
𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 1) ∙ 100        (12) 
Eq. (11) and (12) apply for all steroids and can therefore be used to estimate changes 
of rate constants in all reactions where the medium concentration of the precursor is 
known.  
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B5. Python implementation of secretion rates, flux rates and rate constant 
relative changes calculation  
Below the implementation of the mass balance model system of steroidogenesis 
under steady state conditions. The code for estimation of values and relative 
changes in the first replicate is presented here as an example. The procedure has 
to be expanded in order to include all 6 biological replicates either by repetition of 
the existing code, or by addition of appropriate loops.  
#------ Estimation of secretion rates, fluxes and relative rate constant changes------ 
import numpy as np 
from numpy import array, dot 
import pylab as pl 
import scipy 
from scipy import stats 
import operator 
import numbers 
import cvxopt 
from cvxopt import matrix, solvers 
 
#Definition of data files 
dataCntA = np.loadtxt(“Data from control condition- Replicate A.txt') 
…   # Three dots imply the need to include values or procedures for all replicates 
dataInhA = np.loadtxt(“Data from inhibition condition _replicate A.txt') 
… 
# Parameter definition  
#List of steroids for secretion rates calculations and fluxes 
Name = ['Aldosterone', 'Corticosterone', 'Cortisol', 'Cortisone', '11-Deoxycortisol', '11-
Deoxycorticosterone', 'Pregnenolone', 'Androstenedione', 'DHEA', '17OH-Progesterone', 
'Progesterone', 'Testosterone'] 
fluxes = ['v01', 'v11', 'v12', 'v13', 'v14', 'v21', 'v22', 'v23', 'v31', 'v32', 'v33', 'v34', 'vv1', 'vv2'] 
RCLabels = ['m11','m12','m13','m14','m31','mm1','m22','m23','m33','m34','mm2'] 
 
# F - Medium flow 
F=0.015 
# Calculation of secretion rates 
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fluxcntA = []  
fluxinhA = [] 
… 
fluxcntAVE = [] 
fluxcntSD = [] 
fluxinhAVE = [] 
fluxinhSD = [] 
 
for i in range(1, 13): 
    fcntA = F*scipy.mean(dataCntA[:,i]) 
    fluxcntA.append(fcntA)   
    … 
    fluxcntAVE.append(np.mean([fcntA, … ])) 
    fluxcntSD.append(np.std([fcntA, …])) 
    finhA = F*scipy.mean(dataInhA[:,i]) 
    fluxinhA.append(finhA)    
    … 
    fluxinhAVE.append(np.mean([finhA, …])) 
    fluxinhSD.append(np.std([finhA, …])) 
 
# Quadratic programming matrices 
# stoichiometric matrix of the system 
A = np.loadtxt('A.txt') 
# necessary transformations 
P = matrix(np.matmul(A.transpose(), A) 
# matrix G of the constrain G*v >= 0 
G = matrix(np.loadtxt('G.txt')) 
# matrix h with all elemants equal to 0 
h = matrix(np.loadtxt('H.txt'), tc='d') 
 
# matrix of the control model containing all calculated secretion rates 
qcA = matrix(np.matmul(np.array(fluxcntA).transpose(), Acoeff)) 
sol_cA = solvers.qp(P, qcA, GD, h) 
# matrix of the inhibition model containing all calculated secretion rates 
qiA = matrix(np.matmul(np.array(fluxinhA).transpose(), A)) 
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sol_iA = solvers.qp(P, qiA, GD, h) 
     
#------------------Replicate A-------------------------------------------------------------------------------- 
#intracellular fluxes for control  
v14cntA = fluxcntA[0] 
v13cntA = fAldocntA + fluxcntA[1] 
v12cntA = v13cntA + fluxcntA[5] 
v23cntA = fluxcntA[2] 
v22cntA = v23cntA + fluxcntA[4] 
v33cntA = fluxcntA[11] 
#intracellular fluxes for inhibition  
v14inhA = fluxinhA[0] 
v13inhA = fAldoinhA + fluxinhA[1] 
v12inhA = v13inhA + fluxinhA[5] 
v23inhA = fluxinhA[2] 
v22inhA = v23inhA + fluxinhA[4] 
v33inhA = fluxinhA[11] 
# Difference between fluxes in absolute and percentage numbers 
Dv13a = (v13inhA - v13cntA)*100/v13cntA 
Dv12a = (v12inhA - v12cntA)*100/v12cntA 
Dv23a = (v23inhA - v23cntA)*100/v23cntA 
Dv22a = (v22inhA - v22cntA)*100/v22cntA 
Dv33a = (v33inhA - v33cntA)*100/v33cntA 
DfAldoa = (fAldoinhA - fAldocntA)*100/fAldocntA 
#Calculation of relative % changes in rate constants according to model 
DiffRCA = [] 
DiffRCA.append((np.array(sol_iA[1]*fluxcntA[6])/np.array(sol_cA[1]*fluxinhA[6])-1)*100) 
DiffRCA.append((np.array(sol_iA[2]*fluxcntA[10])/np.array(sol_cA[2]*fluxinhA[10])-
1)*100) 
DiffRCA.append((np.array(sol_iA[3]*fluxcntA[5])/np.array(sol_cA[3]*fluxinhA[5])-1)*100) 
DiffRCA.append((np.array(sol_iA[4]*fluxcntA[1])/np.array(sol_cA[4]*fluxinhA[1])-1)*100) 
DiffRCA.append((np.array(sol_iA[8]*fluxcntA[6])/np.array(sol_cA[8]*fluxinhA[6])-1)*100) 
DiffRCA.append((np.array(sol_iA[12]*fluxcntA[10])/np.array(sol_cA[12]*fluxinhA[10])-
1)*100) 
DiffRCA.append((np.array(sol_iA[6]*fluxcntA[9])/np.array(sol_cA[6]*fluxinhA[9])-1)*100) 
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DiffRCA.append((np.array(sol_iA[7]*fluxcntA[4])/np.array(sol_cA[7]*fluxinhA[4])-1)*100) 
DiffRCA.append((np.array(sol_iA[10]*fluxcntA[8])/np.array(sol_cA[10]*fluxinhA[8])-
1)*100) 
DiffRCA.append((np.array(sol_iA[11]*fluxcntA[7])/np.array(sol_cA[11]*fluxinhA[7])-
1)*100) 
DiffRCA.append((np.array(sol_iA[13]*fluxcntA[9])/np.array(sol_cA[13]*fluxinhA[9])-
1)*100) 
 
#--------------------------End of replicates --------------------------------------------------------- 
# Definition of columns for printing results in txt file. Few examples:  
FluxAverageLabelsCnt = ["v14","v13","v12","v23","v22","v33", "-","-","-","-","-","-" ] 
FluxAverageCnt = [np.mean([v14cntA, …]), np.mean([v13cntA, …]), … ] 
FluxAverageInh = [np.mean([v14inhA, …]), np.mean([v13inhA, …]), …]  
FluxSDCnt = [np.std([v14cntA, …]), np.std([v13cntA, …]), …] 
FluxSDInh = [np.std([v14inhA, …]), np.std([v13inhA, …]), …] 
FluxDiff = [np.mean([Dv14,…]), np.mean([Dv13a, …]), …] 
FluxDiff_SD = [np.std([Dv14a, …]), np.std([Dv13a, …]), …] 
with open("FileName.csv", 'wb') as file: 
    file.write(b'label1, label2, … \n') 
    np.savetxt(file, np.column_stack([array1, array2, …]), delimiter=",", fmt='%s') 
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B6. Numerical example of intracellular flux calculation. 
This is a numerical example of secretion rates and intracellular fluxes calculation for one 
replicate of the control condition in one of our experimental set-ups (under SI_191 
inhibition). This example includes the calculation of the downstream fluxes v12, v13, v14, 
v22, v23 and v33. As discussed in the materials and methods of the manuscript, the 
upstream intracellular fluxes calculation requires more complicated mathematical 
formulations which cannot be done analytically as the downstream fluxes. Prior to this, 
we have collected four hourly samples of the perfusion medium and measured them for 
11 steroids by LC-MS/MS as described in the methods.  
Step 1. Calculation of average flowing medium concentrations  
LC-MS/MS-derived average perfusion medium concentrations of samples one to four for 
our first replicate experiment were estimated and are given in appendix 2, table 1: 
Table 1: Average steroid perfusion medium concentrations 
Steroids Concentrations in nM 
Aldosterone 0.616 
Corticosterone 1.297 
Cortisol 41.729 
11-deoxycortisol 32.976 
11-deoxycorticosterone 5.333 
Pregnenolone 6.991 
Androstenedione 1.760 
DHEA 4.230 
17OH-progesterone 0.679 
Progesterone 0.467 
Testosterone 3.675 
 
Step 2. Calculation of secretion rates  
The second step of the procedure involved calculation of the secretion rates of steroids 
to the flowing medium. The equation used for calculating effluxes is the following, as 
described in materials and methods: 
 𝐽𝑥 = 𝐹 ∙ 𝐶𝑥 
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By applying the measured concentrations from table 1 for each steroid, we obtain the 
secretion rates for all steroids. As an example, we calculate step by step the flux rate of 
cortisol:  
  𝐽𝑐𝑜𝑟𝑡𝑖𝑠𝑜𝑙 = 𝐹 ∙ 𝐶𝑐𝑜𝑟𝑡𝑖𝑠𝑜𝑙  ⇔   𝐽𝑐𝑜𝑟𝑡𝑖𝑠𝑜𝑙 = 0.015
𝑚𝑙
𝑚𝑖𝑛
∗ 41.729 𝑛𝑀
= 0.626
𝑝𝑚𝑜𝑙
𝑚𝑖𝑛
 
All secretion rates calculated in this manner are presented in table 2: 
Table 2: calculated secretion rates in pmol/min  
Aldosterone 0.009 
Corticosterone 0.019 
Cortisol 0.626 
11-deoxycortisol 0.495 
11-deoxycorticosterone 0.080 
Pregnenolone 0.105 
Androstenedione 0.026 
DHEA 0.063 
17OH-progesterone 0.010 
Progesterone 0.007 
Testosterone 0.055 
 
The secretion rates that are involved in the analytical solution of our linear system for the 
estimation of intracellular fluxes are the following (in pmol/min): 
11-deoxycorticosterone: 𝐽11−𝑑𝑒𝑜𝑥𝑦𝑐𝑜𝑟𝑡𝑖𝑐𝑜𝑠𝑡𝑒𝑟𝑜𝑛𝑒 = 0.080        
𝑝𝑚𝑜𝑙
𝑚𝑖𝑛
 
Corticosterone:  𝐽𝑐𝑜𝑟𝑡𝑖𝑐𝑜𝑠𝑡𝑒𝑟𝑜𝑛𝑒 = 0.019        
𝑝𝑚𝑜𝑙
𝑚𝑖𝑛
  
Aldosterone:   𝐽𝑎𝑙𝑑𝑜𝑠𝑡𝑒𝑟𝑜𝑛𝑒 = 0.009        
𝑝𝑚𝑜𝑙
𝑚𝑖𝑛
 
11-deoxycortisol:  𝐽11−𝑑𝑒𝑜𝑥𝑦𝑐𝑜𝑟𝑡𝑖𝑠𝑜𝑙 = 0.495        
𝑝𝑚𝑜𝑙
𝑚𝑖𝑛
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Cortisol:   𝐽𝑐𝑜𝑟𝑡𝑖𝑠𝑜𝑙 = 0.626        
𝑝𝑚𝑜𝑙
𝑚𝑖𝑛
 
Testosterone:  𝐽𝑡𝑒𝑠𝑡𝑜𝑠𝑡𝑒𝑟𝑜𝑛𝑒 = 0.055        
𝑝𝑚𝑜𝑙
𝑚𝑖𝑛
 
 
Step 3. Calculation of intracellular flux rates 
This step involves solving the intracellular fluxes linear system that mathematically 
describes our modeling approximation. The full set of equations is given in table 4 of 
supplementary material. We start from the equation for cortisol: 
𝑣23 =  𝐽𝑐𝑜𝑟𝑡𝑖𝑠𝑜𝑙 ⇔   𝑣23 =  0.626
𝑝𝑚𝑜𝑙
𝑚𝑖𝑛
 
Next we apply the derived secretion and flux rates on the equation for 11-deoxycortisol: 
𝑣22 =  𝑣23 + 𝐽11−𝑑𝑒𝑜𝑥𝑦𝑐𝑜𝑟𝑡𝑖𝑠𝑜𝑙 = 0.626 + 0.495 = 1.121
𝑝𝑚𝑜𝑙
𝑚𝑖𝑛
 
Then we continue solving the equations for the aldosterone pathway: 
𝑣14 =  𝐽𝑎𝑙𝑑𝑜𝑠𝑡𝑒𝑟𝑜𝑛𝑒 ⇔  𝑣14 = 0.009 
𝑝𝑚𝑜𝑙
𝑚𝑖𝑛
 
𝑣13 =  𝑣14 + 𝐽𝑐𝑜𝑟𝑡𝑖𝑐𝑜𝑠𝑡𝑒𝑟𝑜𝑛𝑒 = 0.009 + 0.019 = 0.028 
𝑝𝑚𝑜𝑙
𝑚𝑖𝑛
 
𝑣12 =  𝑣13 + 𝐽11−𝑑𝑒𝑜𝑥𝑦𝑐𝑜𝑟𝑡𝑖𝑐𝑜𝑠𝑡𝑒𝑟𝑜𝑛𝑒 = 0.028 +  0.080 = 0.108 
𝑝𝑚𝑜𝑙
𝑚𝑖𝑛
 
𝑣33 =  𝐽𝑡𝑒𝑠𝑡𝑜𝑠𝑡𝑒𝑟𝑜𝑛𝑒 ⇔ 𝑣33 = 0.055 
𝑝𝑚𝑜𝑙
𝑚𝑖𝑛
 
 
As outlined in materials and methods, this procedure was repeated for all replicates and 
then average values and standard deviations were derived based on those values. For 
a better visualization of the model, we have created figures 1 and 2 of the appendix 2 of 
the supplementary material showing numerical implementations of the model for two 
separate replicates of SI_191 (example solved here) and SI_254, respectively.  
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Supplementary material, figure 1. 
 
Supplementary material, appendix 2, figure 1: representation of a numerical example 
based on the control and inhibition values (hours one to four) for SI_191. Intracellular 
fluxes are presented with blue dotted lines (values in the upper blue boxes) and secretion 
rates from the intracellular environment to cell exterior are presented by double stranded 
lines (values in the lower green boxes).     
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Supplementary material, figure 2. 
 
Supplementary material, appendix 2, figure 2: representation of a numerical example 
based on the control and inhibition values (hours one to four) for SI_254. Intracellular 
fluxes are presented with blue dotted lines (values in the upper blue boxes) and secretion 
rates from the intracellular environment to cell exterior are presented by double stranded 
lines (values in the lower green boxes).    
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B7. Supplementary material for steady state model derived data 
Supplementary material, Figure 1.  
 
 
Supplementary material, Figure 1: Medium concentrations of pregnenolone, 
androstenedione, DHEA, 17OH-progesterone and progesterone under FAD (10nM) and 
MET (10μΜ) treatment in continuous cultivation. Cells were cultured in the ibidi chambers 
under stable medium flow for 8 hours. Time points 1 to 4 hours are control concentrations 
under DMSO treated medium. After 4 hours inhibitors FAD and MET were added to the 
flow medium (time point marked as a black dotted line). 
104 
 
Supplementary material, Figure 2.  
 
 
Supplementary material, Figure 2: Medium concentrations of pregnenolone, 
androstenedione, DHEA, 17OH-progesterone and progesterone under SI_191 (5nM) 
and SI_254 (100nM) treatment in continuous cultivation. Cells were cultured in the ibidi 
chambers under stable medium flow for 8 hours. Time points 1 to 4 hours are control 
concentrations under DMSO treated medium. After 4 hours inhibitors SI_191 and SI_254 
were added to the flow medium (time point marked as a black dotted line).  
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Supplementary material, Figure 3.  
 
 
 
Supplementary material, Figure 3: Proliferation and viability of H295RA cells in batch 
culture following inhibitor treatment. Both proliferation and viability were measured after 
0, 24 and 48 hours under 10nM of FAD (A) and 10μM of MET (B) culture medium. In 
both graphs untreated cells are represented by light gray bars and inhibitor treated cells 
by dark grey.  
 
  
A. 
B. 
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Supplementary material, Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary material, Figure 4: Proliferation and viability of H295RA cells in batch 
culture following inhibitor treatment. Both proliferation and viability were measured after 
0, 24 and 48 hours under 5nM of SI_191 (A) and 100nM of SI_254 (B) in culture medium. 
In both graphs untreated cells are represented by light gray bars and inhibitor treated 
cells by dark grey.  
 
  
B. 
A. 
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Supplementary material, Table 1. Linear system equations for calculating intracellular 
fluxes. 
Equations for the linear system of steroidogenesis under steady state 
conditions 
11-deoxycorticosterone 𝑣12 =  𝑣13 + 𝐽11−𝑑𝑒𝑜𝑥𝑦𝑐𝑜𝑟𝑡𝑖𝑐𝑜𝑠𝑡𝑒𝑟𝑜𝑛𝑒 
 
corticosterone 𝑣13 =  𝑣14 + 𝐽𝑐𝑜𝑟𝑡𝑖𝑐𝑜𝑠𝑡𝑒𝑟𝑜𝑛𝑒 
 
aldosterone 𝑣14 =  𝐽𝑎𝑙𝑑𝑜𝑠𝑡𝑒𝑟𝑜𝑛𝑒  
11-deoxycortisol 𝑣22 =  𝑣23 + 𝐽11−𝑑𝑒𝑜𝑥𝑦𝑐𝑜𝑟𝑡𝑖𝑠𝑜𝑙   
cortisol 𝑣23 =  𝐽𝑐𝑜𝑟𝑡𝑖𝑠𝑜𝑙   
testosterone 𝑣33 =  𝐽𝑡𝑒𝑠𝑡𝑜𝑠𝑡𝑒𝑟𝑜𝑛𝑒  
 
Supplementary material, Table 1: The equations describing the downstream pathway 
reactions of our steady-state based modeling approximation (fig. 1). Each equation 
describes the intracellular conversions of steroids from precursors to products 
(presented by 𝑣𝑖) and the steroid secretion in the flowing medium (presented by 𝐽𝑠𝑡𝑒𝑟𝑜𝑖𝑑  ). 
The calculated steroid concentrations in the perfused medium allow for the calculation 
of the secretion rates (in mol/min) which, subsequently and by applying the derived 
values on the linear system above, allow for calculation of the intracellular fluxes (in 
mol/min).  
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Supplementary material, Table 2. Intracellular flux rates of steroidogenic reactions for 
FAD and MET inhibition 
 
Enzymatic steps and enzymes 
FAD MET 
 Control  Inhibitor  Control  Inhibitor 
cholesterol → pregnenolone 
CYP11A1 flux - v01 1.926 ± 0.283  1.981 ± 0.308 1.674 ± 0.130  1.380 ± 0.140 
pregnenolone → progesterone 
3β-HSD flux - v11 0.996 ± 0.136  1.029 ± 0.161 0.898 ± 0.067  0.738 ± 0.080 
progesterone → 11-deoxycorticosterone 
CYP21A2 flux - v12 0.135 ± 0.012  0.168 ± 0.014 0.192 ± 0.022  0.200 ± 0.022 
11-deoxycorticosterone → corticosterone 
CYP11B1/CYP11B2 flux - v13 0.040 ± 0.007  0.028 ± 0.007 0.051 ± 0.006  0.025 ± 0.010 
corticosterone → aldosterone 
CYP11B2 flux - v14 0.006 ± 0.001  0.003 ± 0.001 0.015 ± 0.002  0.005 ± 0.001 
pregnenolone → DHEA 
CYP17(17α-hydroxylase and 17,20 lyase) flux - v31 0.179 ± 0.040  0.210 ± 0.033 0.125 ± 0.029  0.162 ± 0.032 
progesterone → 17OH-progesterone 
CYP17(17α-hydroxylase) flux - vv1 0.856 ± 0.142  0.850 ± 0.161 0.700 ± 0.047  0.529 ± 0.059 
pregnenolone → 17OH-progesterone 
3β-HSD flux - v21 0.701 ± 0.108  0.686 ± 0.119 0.620 ± 0.050  0.450 ± 0.057 
17OH-progesterone → 11-deoxycortisol 
CYP21A2 flux - v22 1.446 ± 0.248  1.399 ± 0.274 1.251 ± 0.093  0.884 ± 0.118 
11-deoxycortisol → cortisol 
CYP11B1 flux - v23 0.873 ± 0.178  0.532 ± 0.118 0.594 ± 0.061  0.277 ± 0.047 
17OH-progesterone → androstenedione 
CYP17(17,20 lyase) flux - vv2 0.084 ± 0.008  0.109 ± 0.008 0.053 ± 0.008  0.082 ± 0.012 
DHEA → androstenedione 
3β-HSD flux - v32 0.127 ± 0.007  0.167 ± 0.009 0.080 ± 0.012  0.119 ± 0.011 
androstenedione → testosterone 
17β-HSD flux - v33 0.114 ± 0.007  0.160 ± 0.005 0.073 ± 0.006  0.139 ± 0.014 
 
Supplementary material, Table 2: Calculated intracellular fluxes of H295RA cells under 
control and inhibition conditions (before and after inhibition, respectively) for FAD and 
MET treatment. Calculated values are presented in pmol/min as mean and standard 
deviation. 
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Supplementary material, Table 3. Intracellular flux rates of steroidogenic reactions for 
SI_191 and SI_254 inhibition 
 
Enzymatic steps and enzymes 
SI_191 SI_254 
 Control  Inhibitor  Control  Inhibitor 
cholesterol → pregnenolone 
CYP11A1 flux - v01 1.563 ± 0.054  1.841 ± 0.198 2.653 ± 0.096  2.440 ± 0.059 
pregnenolone → progesterone 
3β-HSD flux - v11 0.775 ± 0.021  0.950 ± 0.102 1.395 ± 0.049  1.418 ± 0.028 
progesterone → 11-deoxycorticosterone 
CYP21A2 flux - v12 0.113 ± 0.003  0.160 ± 0.034 0.272 ± 0.018  0.741 ± 0.023 
11-deoxycorticosterone → corticosterone 
CYP11B1/CYP11B2 flux - v13 0.028 ± 0.002  0.017 ± 0.001 0.028 ± 0.001  0.081 ± 0.003 
corticosterone → aldosterone 
CYP11B2 flux - v14 0.010 ± 0.000  0.003 ± 0.000 0.004 ± 0.000  0.011 ± 0.001 
pregnenolone → DHEA 
CYP17(17α-hydroxylase and 17,20 lyase) flux - v31 0.115 ± 0.008  0.148 ± 0.025 0.172 ± 0.012  0.172 ± 0.003 
progesterone → 17OH-progesterone 
CYP17(17α-hydroxylase) flux - vv1 0.656 ± 0.019  0.780 ± 0.071 1.115 ± 0.035  0.665 ± 0.034 
pregnenolone → 17OH-progesterone 
3β-HSD flux - v21 0.552 ± 0.017  0.627 ± 0.057 0.945 ± 0.036  0.691 ± 0.034 
17OH-progesterone → 11-deoxycortisol 
CYP21A2 flux - v22 1.160 ± 0.034  1.336 ± 0.117 1.970 ± 0.066  1.265 ± 0.070 
11-deoxycortisol → cortisol 
CYP11B1 flux - v23 0.629 ± 0.010  0.484 ± 0.016 0.730 ± 0.033  0.467 ± 0.027 
17OH-progesterone → androstenedione 
CYP17(17,20 lyase) flux - vv2 0.036 ± 0.002  0.058 ± 0.009 0.073 ± 0.006  0.078 ± 0.002 
DHEA → androstenedione 
3β-HSD flux - v32 0.047 ± 0.003  0.081 ± 0.013 0.112 ± 0.011  0.112 ± 0.002 
androstenedione → testosterone 
17β-HSD flux - v33 0.052 ± 0.003  0.088 ± 0.014 0.100 ± 0.011  0.121 ± 0.006 
 
Supplementary material, Table 3: Calculated intracellular fluxes of H295RA cells under 
control and inhibition conditions (before and after inhibition, respectively) for SI_191 and 
SI_254 treatment. Calculated values are presented in pmol/min as mean and standard 
deviation. 
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Appendix C – Age and gender-adjusted reference intervals 
Supplementary material, Table 2 
 
Table 1. Polynomial coefficients with standard errors (SE) of fractional polynomials 
following fitting of the models to means and standard deviations (SD) for plasma 
concentrations of androstenedione, DHEA, DHEA-SO4 and pregnenolone according to 
age groups for males and females. All values calculated according the methods outlined 
in the Experimental Design, Materials and Methods (all p-values <0.001, x in years, after 
transformation according to Royston and Wright). 
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Supplementary material, Table 2 
 
Table 2. Polynomial coefficients with standard errors (SE) of fractional polynomials 
following fitting of the models to means and standard deviations (SD) for plasma 
concentrations of corticosterone, 11-deoxycorticosterone, cortisone and 17OH-
progesterone according to age groups for males and females. All values calculated 
according the methods outlined in the Experimental Design, Materials and Methods (all 
p-values <0.001, x in years, after transformation according to Royston and Wright). 
 
  
 
  MALES FEMALES 
C
or
tic
os
te
ro
ne
 
Mean Estimates SE Mean Estimates SE 
Intercept 2.72E+00 3.51E-02 Intercept 1.66E+00 1.18E-02 
(x/0.1)-0.5 -1.01E+00 3.97E-02 (x/0.1)2 1.04E-01 3.26E-03 
log(x/0.1)*(x/0.1)-0.5 -3.08E-01 1.77E-02 log(x/0.1)*(x/0.1)2 -4.19E-02 1.55E-03 
SD     SD     
Intercept 9.49E-01 1.48E-02 Intercept 5.67E-01 3.19E-03 
(x/0.1)-1 7.04E-02 1.11E-02 (x/0.1)   8.68E-02 1.53E-03 
(x/0.1)-0.5 -2.79E-01 2.78E-02 (x/0.1)3 -3.57E-04 2.24E-05 
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-D
eo
xy
co
rt
ic
os
te
ro
ne
 
Mean Estimates SE Mean Estimates SE 
Intercept 4.15E-02 8.86E-04 Intercept 5.22E-03 1.13E-03 
(x/0.1)2 2.05E-03 1.39E-04 (x/0.1)   2.44E-02 9.11E-04 
(x/0.1)3 -1.58E-04 1.57E-05 (x/0.1)2 -1.81E-03 1.20E-04 
SD     SD     
Intercept 3.68E-02 1.72E-03 Intercept 5.32E-02 1.42E-03 
(x/0.1)3 9.22E-04 8.31E-05 log(x/0.1) 1.12E-02 1.39E-03 
log(x/0.1)*(x/0.1)3 -3.69E-04 3.77E-05     
C
or
tis
on
e 
Mean Estimates SE Mean Estimates SE 
Intercept 2.88E+00 2.09E-03 Intercept 2.74E+00 3.98E-03 
(x/0.1)   4.91E-02 1.05E-03 (x/0.1)2 4.52E-02 1.10E-03 
(x/0.1)3 -2.80E-04 1.50E-05 log(x/0.1)*(x/0.1)2 -1.80E-02 5.22E-04 
SD     SD     
Intercept 3.62E-01 8.47E-03 Intercept 2.58E-01 1.21E-03 
log(x/0.1) 6.09E-02 4.55E-03 log(x/0.1) 6.28E-03 1.00E-03 
(x/0.1)0.5 -8.40E-02 7.05E-03 log(x/0.1)2 -1.48E-02 7.31E-04 
17
-H
yd
ro
xy
pr
og
es
te
ro
ne
 Mean Estimates SE Mean Estimates SE 
Intercept 7.57E-01 6.16E-03 - - - 
(x/0.1)2 1.58E-02 1.01E-03 - - - 
(x/0.1)3 -1.30E-03 1.19E-04 - - - 
SD     SD     
Intercept -5.66E-02 3.20E-02 - - - 
(x/0.1)0.5 5.44E-01 3.32E-02 - - - 
log(x/0.1)*(x/0.1)0.5 -1.75E-01 1.14E-02 - - - 
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Zusammenfasung 
 
Steroidhormone der Nebenniere regulieren eine Vielzahl physiologischer Funktionen. 
Ihre Synthese ist streng kontrolliert. Ein Überschuss dieser Hormone führt zu 
Krankheitsbildern, da sie den Metabolismus sowie die kardiovaskulären und 
immunologischen Funktionen des Körpers beeinflussen. Die Strukturen der Aldosteron- 
und Cortisol-produzierenden Enzyme CYP11B2 und CYP11B1 zeigen eine Homologie 
von 93%. Deshalb werden für pharmakologische Therapien hoch-selektive Substanzen 
benötigt. Mittels rechnergestützten Modellen für die Berechnung der metabolischen 
Raten können die Synthesewege der Steroidhormone basierend auf experimentellen 
Daten untersucht werden. Solche Systeme finden breite Anwendung u. a. für die 
Untersuchung der Effekte von endokrin-inhibierenden Chemikalien, Medikamenten oder 
Gen-Manipulationen. Unter Einbezug klinischer Daten kann eine Regressionsanalyse 
dazu beitragen, die Auswirkung solcher Erkrankungen zu definieren sowie 
Referenzwerte für die Charakterisierung der Normalwerte der physiologischen Prozesse 
zu liefern. 
Das Hauptziel dieser Arbeit bestand in der Entwicklung von Modell-Systemen für die 
klinische sowie Grundlagenforschung, welche Mittelwerte für die Untersuchung von 
Dysfunktionen und Erkrankungen der Nebenniere liefern. Zunächst wurde ein Modell-
System basierend auf Massenbilanzen und Reaktionsgleichungen genutzt, um die 
Kinetik der Steroidgenese in humanen Zellen der Nebennierenrinde NCI H295R zu 
charakterisieren. Hierfür wurden 10 Steroide mittels LC-MS/MS analysiert. 
Zeitabhängige Änderungen der Steroidkonzentrationen im Zellkulturmedium nach 
Inkubation mit Angiotensin II, Forskolin und Abirateron wurden bestimmt. Basierend auf 
den experimentellen Daten wurden Modellparameter mit der Methode der kleinsten 
Fehlerquadrate (WLSQ) berechnet. Angiotensin II und Forskolin bewirkten eine 
Änderung der Precursor-Steroide im Zellmedium mit maximalem Anstieg von Aldosteron 
und Cortisol. Eine Inhibierung von 17-Alpha-Hydroxylase/17,20-Lyase durch Abirateron 
führte zu einem Anstieg der Precursor-Steroide und einer Abnahme der Downstream-
Produkte. Abgeleitete Modeleparameter, u.a. Geschwindigkeitskonstanten von 
enzymatischen Reaktionen, quantifizierten die beobachteten und erwarteten 
Änderungen in den Stoffwechselwegen an mehreren Umsetzungsschritten. Diese ersten 
experimentellen Daten verdeutlichten die Wichtigkeit, die Dynamik der Steroidgenese in 
Zellen der Nebenniere zu analysieren. Trotz der Vorteile einer rechnerbasierten Analyse 
verglichen mit den Einzel-Zeitpunkt-Studien, zeigte dieses Modell einige Limitationen 
bezüglich Aufwand, Reproduzierbarkeit und Kosten, welche in einer zweiten Studie 
adressierte wurden.  
Im zweiten Ansatz nutzen wir ein effektives in vitro Assay zur Evaluierung der 
Enzymkinetik basierend auf Berechnungen des intrazellulären Flusses. H295RA-Zellen 
wurden unter konstantem Fluss in kleinen Chamberslides (µ-slide, Ibidi) kultiviert. Die 
Gewinnung der Kontroll-Proben erfolgte jeweils aller 4 Stunden. Über weitere 4 Stunden 
nach Behandlung mit entweder Fadrozole (10nM), Metyrapone (10uM), ASI_191 (5nM), 
einem neuartigen CYP11B2-Inhibitor, oder ASI_254 (100nM), einem neu synthetisierten 
CYP17-Inhibitor, wurden weitere Proben gesammelt. Massenspektrometrische 
Messungen verschiedener Steroide verbunden mit linearem System Computational 
113 
 
Modeling ermöglichten die Berechnung von intrazellulären Flussraten an verschiedenen 
Punkten der Steroidgenese sowie die Beurteilung der Selektivität der Medikamente an 
diesen speziellen Punkten. Eine Behandlung mit Fadrozol, Metyrapon und ASI_191 
bewirkten eine Reduktion des Produktionsflusses von Aldosteron, Corticosteron und 
Cortisol. ASI_254 führte zu einem erhöhten Fluss durch den Mineralcorticoid-Weg und 
zu einer erhöhten Produktion von Aldosteron. CYP17-nachgeschaltete Steroide wurden 
in geringerem Maße produziert. ASI_191 zeigte eine deutlich höhere Selektivität für 
CYP11B2 gegenüber CYP11B1 verglichen mit Fadrozol oder Metyrapon. Unsere Studie 
verdeutlicht die Vorteile eines kontinuierlichen gegenüber eines statischen 
Kultursystems, um die Effekte von Steroidgenese-Inhibitoren zu untersuchen. Die Kultur 
der Zellen unter Strömung stellt ein realistischeres Modell für die Untersuchung von 
Substanz-Effekten dar, ermöglicht eine einfache und schnelle Berechnung der 
intrazellulären Flussraten und bietet eine robuste Methode für Drug Screening oder in 
vitro Untersuchungen von metabolischen Mechanismen.  
In einem dritten Ansatz nutzten wir LC-MS/MS abgeleitete Plasma-Konzentrationen von 
525 Freiwilligen mit (n=227) und ohne (n=298) Hypertonie in Kombination mit 
Regressionmodelling für die Extraktion von alters-  und geschlechtsangepassten 
Referenzintervallen. Die Werte von 16 Steroiden (Pregnenolon, Progesteron, 11-
Deoxycorticosteron, Corticosteron, Aldosteron, 18-Oxocortisol, 18-Hydroxycortisol, 17-
Hydroxyprogesteron, 21-Deoxycortisol, 11-Deoxycortisol, Cortisol, Cortison, 
Dehydroepiandrosteron, Dehydroepiandrosterone-Sulfat, Androstenedion, Testosteron) 
versus Alter und Geschlecht wurden mittels Multivariater fraktionierter Polynomanalyse 
erfolgreich modelliert und liefern Referenzintervalle (2.5 and 97.5%) als eine Funktion 
von Alter und Geschlecht. 
 
Summary 
 
Adrenal steroid hormones, which regulate a plethora of physiological functions, are 
produced via tightly controlled pathways. Adrenal hormone excess associates with 
clinical conditions impacting metabolism and cardiovascular and immune function. 
Aldosterone and cortisol producing enzymes, CYP11B2 and CYP11B1, share 93% 
homology requiring highly selective drugs for pharmacological treatment. Investigations 
of these pathways, based on experimental data, can be facilitated by computational 
modeling for calculations of metabolic rate alterations. Such systems can be utilized in a 
variety of applications including investigating effects of endocrine-disrupting chemicals, 
drugs, gene manipulations. On a human level, regression modelling involving use of 
clinical data can contribute in defining effects of such diseases or providing reference 
data for characterizing normal values of physiological processes. The main subject of 
this thesis was the development of modeling techniques that would benefit basic and 
clinical research by supplying means for investigating adrenal related dysfunctions and 
disease. As a first approach, we used a model system, based on mass balance and 
114 
 
mass reaction equations, to kinetically evaluate adrenal steroidogenesis in human 
adrenal cortex-derived NCI H295R cells. For this purpose a panel of 10 steroids was 
measured by liquid chromatographic-tandem mass spectrometry. Time-dependent 
changes in cell incubate concentrations of steroids were measured after incubation with 
angII, forskolin and abiraterone. Model parameters were estimated based on 
experimental data using weighted least square fitting. Time-dependent angII- and 
forskolin-induced changes were observed for incubate concentrations of precursor 
steroids with peaks that preceded maximal increases in aldosterone and cortisol. 
Inhibition of 17-alpha-hydroxylase/17,20-lyase with abiraterone resulted in increases in 
upstream precursor steroids and decreases in downstream products. Derived model 
parameters, including rate constants of enzymatic processes, appropriately quantified 
observed and expected changes in metabolic pathways at multiple conversion steps. 
Our data from our first approach demonstrated limitations of single time point 
measurements and the importance of assessing pathway dynamics in studies of adrenal 
cortical cell line steroidogenesis. Despite the benefits from a computational approach in 
comparison to the single time point studies, this kind of modeling demonstrated certain 
limitations regarding effort, reproducibility and costs. Therefor a second study was 
conducted in order to address such limitations. As a second approach we introduced an 
effective in vitro assay for evaluation of steroidogenic enzyme kinetics based on 
intracellular flux calculations. H295RA cells were cultured in chambers (µ-Slide, Ibidi) 
under constant medium flow. Four hourly samples were collected (control samples), 
followed by collections over an additional four hours after treatment with either fadrozole 
(10nM), metyrapone (10uM), ASI_191 (5nM), a novel CYP11B2 inhibitor or ASI_254 
(100nM), a newly synthesized CYP17 inhibitor. Mass spectrometric measurements of 
multiple steroids combined with linear system computational modeling facilitated 
calculation of intracellular flux rates at different steroidogenic pathway steps and 
assessment of the selectivity of drugs for those specific steps. While treatment with 
fadrozole, metyrapone and ASI_191 all resulted in reductions in fluxes of aldosterone, 
corticosterone and cortisol production, treatment with ASI_254 led to increased flux 
through the mineralocorticoid pathway and increased production of aldosterone with 
reduced production of steroids downstream of CYP17. Comparisons of changes in 
intracellular fluxes revealed much higher selectivity of ASI_191 for CYP11B2 over 
CYP11B1 compared to fadrozole or metyrapone. Our study demonstrates the 
advantages of continuous culture systems over static systems for studying effects of 
steroidogenic inhibitors. By culturing cells under perfusion the methodology establishes 
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a more realistic model for investigating drug effects, provides for simple and rapid 
calculations of intracellular fluxes and offers a robust method for drug screening or in 
vitro investigations of metabolic mechanisms. As a third approach we utilized LC-MS/MS 
derived plasma concentrations for each of 525 normotensive and hypertensive 
volunteers with (n=227) and without (n=298) hypertension in combination with regression 
modeling for the extraction of age and gender-adjusted reference intervals. Values of 8 
steroids (pregnenolone, 11-deoxycorticosterone, corticosterone, 17-
hydroxyprogesterone, cortisone, dehydroepiandrosterone, dehydroepiandrosterone-
sulfate, androstenedione) versus age and gender were modelled via multivariate 
fractional polynomial analysis successfully providing with 0.5 and 99.5% reference 
intervals as a function of age and gender.  
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